Investigations on the role of the IGF2 mRNA-binding protein p62 and the long non-coding RNA H19 in cell culture and in vivo models of hepatocellular carcinoma by Hubig, Christina Stefanie
  
Investigations on the role of the IGF2 mRNA-
binding protein p62 and the long non-coding 
RNA H19 in cell culture and in vivo models  
of hepatocellular carcinoma 
 
 
Dissertation 
zur Erlangung des Grades  
des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät 
der Universität des Saarlandes 
 
 
 
von 
Christina Stefanie Hubig 
 
Saarbrücken 
2018 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag des Kolloquiums:  10.12.2018 
Dekan:     Prof. Dr. Guido Kickelbick 
Berichterstatter:    Prof. Dr. Alexandra K. Kiemer 
     Prof. Dr. Claus-Michael Lehr 
Vorsitz:    Prof. Dr. Marc Schneider 
Akad. Mitarbeiter :  Dr. Sascha Tierling 
  
Contents 
I 
 
Contents 
 
Abstract .......................................................................................................................... 1 
Zusammenfassung ........................................................................................................ 2 
Introduction .................................................................................................................... 3 
1. Hepatocellular carcinoma ......................................................................................... 4 
1.1 HCC: Risk factors ................................................................................................ 5 
1.2 HCC: Therapy ..................................................................................................... 5 
2. Long non-coding RNAs ............................................................................................ 7 
2.1 The lncRNA H19 ................................................................................................. 8 
3. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62 ........................ 10 
4. Aim of the present work .......................................................................................... 12 
Chapter 1 ...................................................................................................................... 13 
Introduction ................................................................................................................ 14 
Results ....................................................................................................................... 15 
Discussion .................................................................................................................. 17 
Chapter 2 ...................................................................................................................... 18 
Introduction ................................................................................................................ 19 
Results ....................................................................................................................... 21 
Discussion .................................................................................................................. 37 
Chapter 3 ...................................................................................................................... 39 
Introduction ................................................................................................................ 40 
Results ....................................................................................................................... 42 
Discussion .................................................................................................................. 58 
Chapter 4 ...................................................................................................................... 63 
Introduction ................................................................................................................ 64 
Results ....................................................................................................................... 65 
Discussion .................................................................................................................. 67 
Chapter 5 ...................................................................................................................... 69 
Introduction ................................................................................................................ 70 
Contents 
II 
 
Results ....................................................................................................................... 71 
Discussion .................................................................................................................. 75 
Materials and Methods ................................................................................................ 76 
1. Materials ................................................................................................................. 77 
2. Mice ........................................................................................................................ 78 
2.1 Animal welfare................................................................................................... 78 
2.2 Generation of p62 transgenic H19 knockout mice............................................. 78 
2.3 Genotyping ........................................................................................................ 79 
2.4 Treatment .......................................................................................................... 80 
2.5 Preparation of liver tissue .................................................................................. 81 
2.6 Histological and immunohistological analyses of mouse livers ......................... 82 
3. Cell culture ............................................................................................................. 82 
3.1 Cell lines ........................................................................................................... 82 
3.2 H19 knockdown ................................................................................................. 83 
3.3 Stable H19 overexpression ............................................................................... 83 
3.4 Establishment of chemoresistant cells .............................................................. 83 
3.5 Cytotoxicity assay (MTT assay) ........................................................................ 84 
3.6 Clonogenicity assay .......................................................................................... 85 
4. RNA isolation and quantitative real-time RT-PCR (qPCR) ..................................... 85 
5. DNA methylation analysis ...................................................................................... 88 
5.1 DNA extraction and bisulfite conversion ............................................................ 88 
5.2 Single nucleotide primer extension (SNuPE) .................................................... 89 
5.3 Local deep bisulfite sequencing (Bi-PROF) ...................................................... 90 
6. Western blot analysis ............................................................................................. 91 
7. RAC1 pull-down assay ........................................................................................... 91 
8. ROS assay ............................................................................................................. 92 
9. Bioinformatic analyses ........................................................................................... 92 
9.1 TCGA data ........................................................................................................ 92 
9.2 GEO datasets.................................................................................................... 93 
10. Clinical samples ................................................................................................... 93 
11. Microdissection and RT-PCR ............................................................................... 94 
12. H19 RNA immunoprecipitation ............................................................................. 94 
13. RFLP (restriction fragment length polymorphism) analysis .................................. 95 
Contents 
III 
 
14. Ki67 staining ......................................................................................................... 96 
15. Chromogenic in situ hybridization (CISH) ............................................................. 96 
16. Statistics ............................................................................................................... 97 
Supplemental information .......................................................................................... 99 
References ................................................................................................................. 105 
Abbreviations ............................................................................................................. 126 
Publications ............................................................................................................... 132 
Danksagung ............................................................................................................... 134 
  
 
 
 
 
Für meine Eltern 
Evelyn und Jürgen Schultheiß 
  
 
 
Abstract 
1 
 
Abstract 
 
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related 
death worldwide mainly due to late diagnosis and its highly resistant nature resulting in 
limited therapeutic options. HCC development and progression is characterized by a 
dysregulation of RNA-binding proteins (RBPs) and long non-coding RNAs (lncRNAs). 
In a mouse model of diethylnitrosamine-induced hepatocarcinogenesis, the lncRNA H19 
showed tumor-suppressive and anti-proliferative actions, which were confirmed in human 
hepatoma cell lines. Since HCC evolves from an inflammatory environment, the anti-
inflammatory action of H19 found in our mouse model underlines its tumor-preventive 
action. 
Chemoresistance is a major problem for the efficacy of systemic HCC therapy. H19 was 
downregulated during chemoresistance due to altered methylation at the H19 promoter 
and sensitized hepatoma cells towards chemotherapeutic drugs. 
The expression of H19 was induced by the transgenic expression of the RBP p62, which 
promoted genomic instability and thereby a more aggressive phenotype of HCC through 
a DLK1-RAC1-ROS axis. A H19 knockout only slightly increased the tumor-promoting 
effect of p62. 
Taken together, H19 antagonized hepatocarcinogenesis by preventing three important 
hallmarks of cancer: proliferation, inflammation, and chemoresistance. The tumor-
suppressive and chemosensitizing functions of H19 could provide new opportunities to 
overcome chemoresistance and improve the options of HCC therapy. 
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Zusammenfassung 
 
Das Hepatozelluläre Karzinom (HCC) ist aufgrund begrenzter Therapieoptionen, die 
hauptsächlich aus späten Diagnosen und ausgeprägter Chemoresistenz resultieren, 
weltweit die zweithäufigste krebsbedingte Todesursache. Eine Dysregulierung von 
mRNA-bindenden Proteinen (RBPs) und langen nicht-codierenden RNAs (lncRNAs) ist 
charakteristisch für die Entstehung und Progression des HCCs. 
Im Mausmodell mit Diethylnitrosamin-induzierter Hepatokarzinogenese zeigte die lncRNA 
H19 eine tumorunterdrückende und proliferationshemmende Wirkung, welche in 
humanen Hepatomzelllinien bestätigt werden konnte. 
Da sich HCC aus einer entzündlichen Umgebung heraus entwickelt, untermauert die 
entzündungshemmende Wirkung von H19 seine tumorpräventive Funktion. 
H19 war aufgrund veränderter Promotor-Methylierung in der Chemoresistenz - dem 
Hauptproblem der systemischen HCC-Therapie - herabreguliert und erhöhte die 
Empfindlichkeit von Hepatomzelllinien gegenüber Chemotherapeutika. 
Das RBP p62 induzierte die H19-Expression, förderte die genomische Instabilität über 
einen DLK1-RAC1-ROS-Weg und begünstigte dadurch die Entstehung eines aggressiven 
HCC-Phänotyps. Ein H19-Knockout erhöhte die tumorfördernde Wirkung von p62 nur 
gering. 
H19 antagonisiert die Hepatokarzinogenese durch Unterdrückung von Proliferation, 
Entzündung und Chemoresistenz. Die tumorpräventive und chemosensibilisierende 
Wirkung von H19 könnte neue Möglichkeiten zur Überwindung der Chemoresistenz und 
Verbesserung der HCC-Therapie eröffnen. 
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1. Hepatocellular carcinoma 
 
Cancer is the leading cause of death worldwide (World-Health-Organization, 2008). 
Whereas the mortality of most types of cancer is declining due to early diagnosis and 
highly efficient therapies, the mortality of liver cancer has still dramatically increased in 
men and women during the past 2 decades (Sia et al., 2017) (Figure 1). Regarding liver 
cancer patients in Germany, only 14% of male and 11% of female patients survive for 
more than 5 years (www.krebsdaten.de; Krebs in Deutschland für 2013/2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mortality trends of patients with different types of malignancies in the United States from 
1990 to 2009. From Sia et al., 2017. 
 
With almost 800,000 new cases annually, hepatocellular carcinoma (HCC) is the 
predominant type of primary liver cancer (Llovet et al., 2016) and the second most 
common cause of cancer-related deaths worldwide (Stewart & Wild, 2014).  
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The cellular origin of HCC are hepatocytes, which constitute 60-80% of the liver mass (Sia 
et al., 2017). Due to chronic injury, hepatocytes develop genetic alterations and defective 
cell cycle regulation leading to promoted cellular growth and resisting cell death (El-Serag 
& Rudolph, 2007). 
 
1.1 HCC: Risk factors 
 
The risk factors for the development of HCC vary by region. In Africa and Asia, hepatitis 
B or hepatitis C virus infections and the consumption of aflatoxin B1-contaminated food 
are the main risk factors. In the Western world, chronic alcoholic fatty liver disease (AFLD) 
and non-alcoholic fatty liver disease (NAFLD) are the leading risk factors for HCC (El-
Serag & Rudolph, 2007, Ozakyol, 2017). AFLD is triggered by heavy alcohol abuse for 
several years (Ozakyol, 2017) and NAFLD develops in consequence of insulin resistance, 
steatosis, oxidative stress, and inflammation (Petta & Craxi, 2010). Further risk factors for 
HCC development are cigarette consumption and the intake of oral contraceptives, which 
are also commonly used in Western countries (Bosch et al., 2004). 
 
1.2 HCC: Therapy 
 
Since 1999, HCC is classified by the Barcelona Clinic Liver Cancer (BCLC) staging 
system for the determination of the best treatment options (Llovet et al., 1999). Curative 
therapies, realized by resection of the tumor tissue or liver transplantation, are advised 
only in early HCC stages and realizable for only 10-30% of the patients (Lau & Lai, 2008). 
Palliative treatments for patients with intermediate or advanced HCC include the 
multikinase inhibitor sorafenib (standard first-line systemic therapy since 2008) and the 
anthracycline doxorubicin (used in combination with sorafenib) (EASL-Clinical-Practice-
Guidelines, 2018, Raymond et al., 2012, Wörns et al., 2009). Sorafenib inhibits tumor cell 
proliferation and angiogenesis, and induces apoptosis by targeting serine/threonine and 
tyrosine kinases (Liu et al., 2006, Wilhelm et al., 2004). Doxorubicin exerts its cytotoxicity 
by intercalation into DNA and thereby deactivating topoisomerase II through strong 
binding (Cutts et al., 2005). 
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The highly resistant nature of HCC presents a major hindrance to the efficacy of systemic 
treatments. Factors mediating chemoresistance of HCC are p53 mutations, 
overexpression of topoisomerase IIa, and enhanced cellular efflux by drug transporters, 
e.g. the multi-drug resistance protein 1 (MDR1) (Hussain et al., 2007, Park et al., 1994, 
Watanuki et al., 2002). 
Due to the rising incidence and lack of suitable therapies, the investigation of underlying 
mechanisms in the development and resistance of hepatocellular carcinoma is of utmost 
importance.  
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2. Long non-coding RNAs 
 
While only 1.2% of the transcribed human genome encodes proteins (IHGS-Consortium, 
2004, Ransohoff et al., 2018), the remaining part is transcribed into a group of non-coding 
RNAs (ncRNAs) (Djebali et al., 2012) consisting of long non-coding RNAs (lncRNAs), 
ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs), small 
nucleolar RNAs (snoRNAs), telomere-associated RNAs, microRNAs (miRNAs), small 
interfering RNAs (siRNAs), and Piwi-associated RNAs (piRNAs) (Blackburn & Collins, 
2011, Czech & Hannon, 2011, Feuerhahn et al., 2010, Henras et al., 2004, Kim et al., 
2009, Okamura & Lai, 2008, Peculis, 2000, Siomi et al., 2011, Xiao et al., 2002) (Figure 
2). 
 
 
 
Figure 2: The human genome consisting of translated and non-translated genes. Percentage values 
were taken from Ransohoff et al., 2018. 
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LncRNAs are defined as autonomously transcribed RNAs longer than 200 nucleotides 
with minimal coding potential (Ransohoff et al., 2018) that can be found in the nucleus 
as well as in the cytoplasm (Batista & Chang, 2013). They are able to bind DNA, 
proteins, or other RNAs (such as miRNAs) (Batista & Chang, 2013, Guttman & Rinn, 
2012, Rinn & Chang, 2012). Thereby, almost all biological processes are affected by 
lncRNAs, for example, epigenetic silencing of gene expression, mRNA splicing, mRNA 
decay, and translation (Wapinski & Chang, 2011). By regulating e.g. apoptosis, 
proliferation, and angiogenesis, lncRNAs are important players in cancer development 
(Schmitt & Chang, 2016, Tsai et al., 2011). 
 
2.1 The lncRNA H19 
 
One example of cancer-associated lncRNAs is H19. The H19 gene, located on 
chromosome 11p15.5 in the human system and on chromosome 7 in mice, is maternally 
imprinted (Rachmilewitz et al., 1992). The enhancer elements - binding and thereby 
activating the H19 promoter - are also used by the insulin-like growth factor 2 (IGF2) gene. 
IGF2 is located around 80 kb adjacent to H19 and reciprocally expressed (Rachmilewitz 
et al., 1992). The H19 gene contains 5 exons, seperated by 4 introns, and is transcribed 
by the RNA polymerase II. The transcript is spliced, polyadenylated, capped, and exported 
into the cytosol (Gabory et al., 2010). Although the expression of H19 is dramatically 
repressed after birth except for skeletal muscles and the heart muscle (Gabory et al., 
2010), a reactivation of the H19 gene in different tumor types, including HCC, has been 
reported (Matouk et al., 2013, Raveh et al., 2015, Zhou et al., 2017). 
 
The known functions of H19 are, in part, mediated by the binding of proteins. Thereby, it 
interacts with transcription factors (Luo et al., 2013, Monnier et al., 2014), tumor-
suppressors, e.g. p53 (Yang et al., 2012), and mRNA-binding proteins, such as IGF2 
mRNA-binding protein 1 (IGF2BP1) and the K homology-type splicing regulatory protein 
(KSRP) (Giovarelli et al., 2014). H19 can also act through microRNA-binding: the tumor-
suppressive miRNAs miR-200 and let-7 are well described H19 targets (Zhou et al., 2017). 
The role of H19 in tumor progression is controversially discussed. Although most 
hallmarks of cancer - including proliferation, apoptosis, inflammation, metastasis, and 
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invasion (Hanahan & Weinberg, 2011) - have been linked to H19, it is not clear whether it 
acts as an oncogene or as a tumor-suppressor (Chen et al., 2016, Li et al., 2016, Ohtsuka 
et al., 2016, Raveh et al., 2015, Yang et al., 2012, Yoshimizu et al., 2008, Yu et al., 2013). 
 
H19 is a precursor for the micro RNA miR-675, located in H19`s first exon (Cai & Cullen, 
2007). Numerous targets of miR-675 have been found, some of them with oncogenic and 
others with tumor-suppressive function. Examples for miR-675 targets are the tumor-
suppressor retinoblastoma (Rb) (Tsang et al., 2010), the anti-apoptotic Fas-associated 
via death domain (FADD) (Yan et al., 2017), and the proliferation- and migration-
associated receptors insulin-like growth factor 1 receptor (IGF1R) (Keniry et al., 2012) and 
vitamin D receptor (VDR) (Chen et al., 2017). In addition, miR-675 has been associated 
with epithelial to mesenchymal transition (EMT), and with its reverse process (Djebali et 
al.), which are important steps in invasion and metastasis (Raveh et al., 2015). Vennin et 
al. reported an enhanced tumorigenesis and metastasis of breast cancer cells due to miR-
675 by targeting the ubiquitin ligase E3 family (c-Cbl and Cbl-b) (Vennin et al., 2015). In 
contrast, miR-675 represses metastasis of prostate cancer by binding the mRNA of 
transforming growth factor beta induced protein (TGFBI) (Zhu et al., 2014). Hence, the 
role of miR-675 in cancer progression is also conflicting. 
 
Though the H19 RNA was classified as non-coding (Brannan et al., 1990), a 26 kDa 
protein derived from H19 was described in 2012 (Gascoigne et al., 2012). The biological 
action of this protein has not been analyzed so far. Since Zeisel and Baumert predicted a 
biological function of such peptides derived from non-protein coding genes in HCC 
development (Zeisel & Baumert, 2016), functional implications of these peptides should 
be considered in the investigations of H19 and its function.  
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3. The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62 
 
The human genome encodes for 1,542 mRNA-binding proteins (RBPs) (Gerstberger et 
al., 2014) with some of them linked to the major steps in cancer development and 
progression, such as proliferation, apoptosis, angiogenesis, metastasis, and inflammation 
(Wang et al., 2016a). RBPs post-transcriptionally regulate their target mRNAs by binding 
sequences mainly located in the untranslated region (Miki et al., 1994, Newman et al., 
2015). 
 
The insulin-like growth factor 2 (IGF2) mRNA-binding proteins (IMPs) belong to the cancer 
associated RBPs (Dai et al., 2017, Jeng et al., 2008). The IMP family consists of IMP-1, 
IMP-2, and IMP-3, which share two RNA recognition motifs and four hnRNP K homology 
domains.  
IMPs target the 5‘-UTR of the IGF2-leader 3 mRNA (Liao et al., 2005, Nielsen et al., 1999) 
and thereby affect its processing. IGF2 is an oncofetal growth factor protein, typically 
repressed after birth (Takeda et al., 1996) and reactivated in cancers including HCC (Lu 
et al., 2005), where it exerts anti-apoptotic action by binding the IGF1 receptor (Nielsen, 
1992, Resnicoff et al., 1995).  
Beside IGF2, thousands of other IMP-targets were described (Hafner et al., 2010). IMP-1 
and IMP-3 protect lots of mRNAs - including oncogenes and stemness maintenance 
genes - from let-7-dependent silencing (Degrauwe et al., 2018). 
IMP-1 binds and controls the transport of actin beta (Farina et al., 2003) and E-cadherin 
(Conway et al., 2016), which are implicated in the stabilization of cell-cell contacts and 
adhesions, and targets BCL2 resulting in apoptosis protection (Conway et al., 2016). 
These data underline the importance of IMPs in cancer initiation and progression. 
 
p62 (IMP2-2) - a splice variant of IMP-2 lacking exon 10 - was originally identified as an 
autoantigen in an HCC patient (Zhang et al., 1999). Therefore, the detection of anti‐p62 
autoantibodies was suggested as a biomarker in diagnostics and monitoring of cancer 
(Liu et al., 2013). Several studies describe an overexpression of p62 in human HCC 
tissues (Kessler et al., 2015, Kessler et al., 2013, Lu et al., 2001, Qian et al., 2005) and 
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its oncogenic potential was demonstrated in a transgenic mouse model (Kessler et al., 
2015). 
Since IMPs target the reciprocally imprinted lncRNA H19 and participate its localization 
(Runge et al., 2000), a link between p62 and H19 expression was hypothesized. Indeed, 
a liver-specific overexpression of p62 in transgenic mice caused H19 overexpression 
(Tybl et al., 2011), but an interaction between p62 and H19 affecting tumorigenesis 
remained unexplored so far. 
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4. Aim of the present work 
 
Dysregulation of RBPs and lncRNAs are features of HCC development and progression. 
Uncovering their modes of action will help to improve the therapy of this highly resistant 
type of tumor. 
The RBP p62 and H19, a lncRNA affected by p62, are associated with 
hepatocarcinogenesis. p62 is overexpressed in HCC and acts as tumor promoter but the 
underlying mechanism of its action is not completely clarified so far. The role of H19 in 
tumor progression is controversially discussed. 
 
The work schedule of this research project addresses questions about: 
 
1) The tumor-promoting action of p62 
2) The role of H19 in the tumor-promoting action of p62 
3) The role of H19 in carcinogenesis and chemoresistance of HCC 
4) H19 as molecular sponge 
5) The role of two proteins derived from the H19 locus 
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Introduction 
 
Hepatocellular carcinoma mostly evolves in an environment characterized by chronic 
inflammation (chronic hepatitis). In the majority of cases this hepatitis results from either 
virus infection or alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease 
(NAFLD) (Castello et al., 2010, Koyama & Brenner, 2017). 
The mRNA-binding protein p62, identified in 1999 (Zhang et al., 1999), induces steatosis 
as a pre-stage of steatohepatitis (Tybl et al., 2011). The vulnerability of mice expressing 
the p62 transgene to the development of steatohepatitis is increased (Simon et al., 2014a) 
and inflammatory processes are amplified (Kessler et al., 2014, Laggai et al., 2014, Simon 
et al., 2014a, Simon et al., 2014b). Furthermore, in p62 transgenic mice genomic instability 
was induced and levels of thiobarbituric acid reactive substances (TBARS) - as indicators 
of oxidative stress - were elevated after short-term treatment with the carcinogen 
diethylnitrosamine (DEN) (Kessler et al., 2015). Oxidative stress is a feature of 
inflammation that is mediated by high levels of reactive oxygen species (ROS) (Block & 
Gorin, 2012). For HCC, an increase of ROS levels from early to advanced stages has 
been described (Lim et al., 2008). By promoting not only inflammation but also genomic 
instability, immortality, angiogenesis, and metastasis (Block & Gorin, 2012, Hanahan & 
Weinberg, 2011), ROS play an important role in carcinogenesis and tumor progression. 
The generation of ROS can be induced by the small GTPase RAC1 (Fürst et al., 2005), 
the expression of which was also increased in livers of p62 transgenic mice (Kessler et 
al., 2015). Furthermore, the elevated Rac1 expression strongly correlates with the 
expression of the hepatic stem cell marker delta-like 1 homolog (Dlk1) in the p62 
transgenic mouse model as well as in human HCC (Kessler et al., 2015). 
In this study, the relation between DLK1, RAC1, and ROS production was analyzed. 
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Results 
 
Mechanism of p62-triggered ROS generation 
 
To test the hypothesis that Dlk1 was responsible for the increased genomic instability 
found in livers of p62 transgenic mice (Kessler et al., 2015), its effect on RAC1 activity 
and ROS generation was examined in vitro using HepG2 cells. The level of activated 
RAC1 protein in HepG2 cells was significantly elevated after treatment with DLK1 for 5 
min as detected by pull-down assay (Figure 1A, B). Cells treated with DLK1 revealed 
increased ROS production (Figure 1C), which was completely abrogated by pre-
incubation with the RAC1 inhibitor NSC23766 (Figure 1D). These data supported the 
hypothesis that DLK1 triggered ROS generation through RAC1.  
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Figure 1: DLK1-RAC1 driven ROS generation. (A) Representative pull-down assay with activated RAC1 
and total RAC1 in untreated HepG2 cells (co) and after treatment with 1 µg/ml DLK1 protein for 2 and 5 min. 
(B) Levels of activated RAC1 in untreated HepG2 cells (co) and after treatment with 1 µg/ml DLK1 protein 
for 5 min (DLK1) normalized to total RAC1 (n=4, singles and duplicates). (C, D) ROS increase [%]: (C) in 
HepG2 cells after treatment with 0.5 µg/ml DLK1, 1 µg/ml DLK1, or 300 µM H2O2 (positiv control) for 0-30 
min normalized to untreated HepG2 cells (n=1, quintuplicates). (D) after treatment with DLK1, RAC1 inhibitor 
NSC23766 (NSC), or both (DLK1 + NSC), normalized to untreated HepG2 cells; H2O2-induced ROS 
formation was set as 100% (n=2, quintuplicates). The p values were calculated by two-sample t-test or 
ANOVA combined with Bonferroni post hoc test.  
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Discussion 
 
The IMP p62 is overexpressed in different types of cancer including HCC (Dai et al., 2017). 
In glioblastoma, p62 preserves stem cells and promotes their tumor-initiating capacity 
(Degrauwe et al., 2016). Cancer stem cells have also been identified in HCCs (Cho & 
Clarke, 2008) and are linked to poor prognosis (Guo et al., 2014). 
In this study a correlation between p62 and the hepatic stem cell marker Dlk1 was found. 
The expression of DLK1 is under epigenetic control and dysregulated in HCC (Huang et 
al., 2007). It corresponds with poor patient survival and was suggested as prognostic 
factor of liver cancer (Jin et al., 2008). Regarding the function of DLK1, an induction of 
RAC1 by DLK1 had been found in mouse embryonic fibroblasts (Wang et al., 2010). Our 
data confirmed this DLK1-caused induction of RAC1 in the hepatoma cell line HepG2. 
RAC1 is highly overexpressed in HCC (Kessler et al., 2015) and correlates with HCC 
metastasis by upregulation of the transcriptional activation of the vascular endothelial 
growth factor (Lee et al., 2006). Activated RAC1 induces ROS generation (Fürst et al., 
2005). In HepG2 cells, elevated ROS levels due to increased RAC1 activity was 
determined. Increased ROS generation results in genomic instability (Block & Gorin, 
2012), which was also found in tumors of p62 transgenic mice with elevated Rac1 
expression (Kessler et al., 2015). Interestingly, in gallbladder cancer, p62 also correlates 
with Rac1 expression and the same Rac1-ROS mechanism was suggested (Kessler et 
al., 2017). 
Taken together, the tumor-promoting action of p62 is, in part, mediated by oxidant actions. 
The underlying mechanism includes the DLK1-facilitated induction of RAC1 as an 
enhancer of ROS generation. The genomic instability - as a consequence of increased 
ROS generation - is linked to an aggressive tumor phenotype in the p62 transgenic mouse 
model (Kessler et al., 2015). 
 
These data were published in: Kessler S. M., Laggai S., Barghash A., Schultheiss C. S., 
Lederer E., Artl M., Helms V., Haybaeck J., and Kiemer A. K. (2015) IMP2/p62 induces 
genomic instability and an aggressive hepatocellular carcinoma phenotype. Cell Death 
and Disease, 6(10), e1894.  
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Chapter 2 
 
The role of H19 in the tumor-promoting action of p62 
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Introduction 
 
Hepatocarcinogenesis is a multistep process that requires a specific microenvironment 
often charecterized by chronic inflammation, changes in the cellular matrix, and altered 
cell signaling (Sia et al., 2017). Beside hepatocytes as cells of origin, different cell types 
are involved in HCC progression, e.g. immune cells administrating an altered immune 
response and activated stellate cells secreting collagen leading to fibrosis (Eng & 
Friedman, 2000, Hanahan & Weinberg, 2011). Hence, analysis of single cell lines is not 
sufficient for the investigation of HCC pathogenesis and several mouse models - class-
divided into chemically induced models, xenograft models, and genetically modified 
models - are in use (Heindryckx et al., 2009). 
The genetically modified models are composed of mice expressing hepatitis B/C virus 
genes, lacking tumor-suppressor genes, or overexpressing oncogenes, e.g. Myc, β-
catenin, or p62 (Heindryckx et al., 2009, Kessler et al., 2015, Yan et al., 2018). 
p62 has an important role in HCC initiation and progression by affecting inflammation and 
genomic instability (Kessler et al., 2015). The p62 transgenic mouse model has been used 
for the functional analysis of p62 and contributed to the current knowledge on this mRNA 
binding protein (Kessler et al., 2015, Kessler et al., 2013, Laggai et al., 2014, Simon et al., 
2014a, Simon et al., 2014b, Tybl et al., 2011). A complex mechanism enables the liver-
specific expression of human p62 in the p62 transgenic mice: p62 expression is under 
control of the transrepressive responsive element cytomegaly virus promoter (TRE-
CMVmin promoter) that can be activated by a transactivator (TA). To induce p62 
expression, mice need to be crossed with transgenic mice carrying a TA, the expression 
of which is controlled by a liver-enriched activator protein promoter (LAP promoter) (LT2 
mice). In the obtained p62 positive and LT2 positive mice, the TA is liver-specifically 
expressed and activates the TRE-CMVmin promoter resulting in the expression of human 
p62 (Tybl et al., 2011). 
p62 has been described to promote steatosis, steatohepatitis, fibrosis, and DEN-induced 
hepatocarcinogenesis (Kessler et al., 2015, Laggai et al., 2014, Simon et al., 2014a, Tybl 
et al., 2011). However, p62 transgenic mice do not spontaneously develop tumors. 
Therefore, a chemically induced mouse model was used to trigger hepatocarcinogenesis, 
i.e. the carcinogen DEN model, which leads to DNA damage and induction of oxidative 
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stress (Heindryckx et al., 2009). Previous analyses of the p62 transgenic mouse model 
revealed a significanly upregulated hepatic expression of the lncRNA H19 (Tybl et al., 
2011). H19 is involved in tumorigenesis, but its function is a subject of controversy (Chen 
et al., 2016, Li et al., 2016, Ohtsuka et al., 2016, Raveh et al., 2015, Yang et al., 2012, 
Yoshimizu et al., 2008, Yu et al., 2013). Interestingly, the extent of H19 overexpression 
was lower in tumor-bearing livers of p62 transgenic mice treated with the carcinogen DEN 
(Laggai, 2014). These findings led us to the hypothesis that H19 has tumor-suppressive 
functions. 
Two different H19 knockout mouse models are known from the literature: the H19∆13 and 
the H19∆3 model. The H19∆13 mice carry a 13 kb deletion encompassing the H19 gene 
and its upstream region containing sequences for the control of H19 and Igf2 expression. 
This results in lack of H19, but biallelic Igf2 expression (Leighton et al., 1995). Since Igf2 
also promotes carcinogenesis (Lu et al., 2005, Nielsen, 1992, Resnicoff et al., 1995), this 
mouse model is not suitable to exclusively analyse the function of H19. In our study, the 
H19∆3 mice, which carry a 3 kb deletion of H19 and show only slightly increased Igf2 
expression (Ripoche et al., 1997), were investigated. The H19∆3 mice were crossed with 
p62 transgenic mice to clarify whether H19 exerts tumor-suppressive action in the p62 
transgenic mouse model. 
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Results 
 
To elucidate the function of H19 in the p62 transgenic mouse model, p62 transgenic mice 
(Tybl et al., 2011) were crossed with H19 deficient mice (Gabory et al., 2010, Ripoche et 
al., 1997) and treated with DEN to trigger HCC development. 
 
H19 ko/p62 tg mice: body and liver weight 
 
H19 ko mice and the respective wild-types differed in body weight (Figure 1A, B). The 
highest body weights were detected for H19 ko/p62 tg mice. The body weight of H19 
ko/p62 tg mice was significantly higher compared to H19 wt/p62 tg mice in both sexes and 
treatment groups. In female mice, the same weight-increasing effect of H19 knockout was 
detected without the p62 transgenic background (Figure 1A, B). Considering all 
genotypes, sexes, and treatments, mice containing the H19 knockout revealed on 
average a 11.5% higher body weight compared to H19 wild-type mice. 
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Figure 1: Body weight of female (left panels) and male (right panels) (A) untreated (co) and (B) DEN-
treated (DEN) mice (co n=10-23, DEN n=20-25). The p values were calculated by Mann-Whitney U test or 
ANOVA combined with Bonferroni post hoc test. 
 
 
Similar trends were found for the liver weights: the highest liver weights were detected for 
H19 ko/p62 tg mice and the liver weights of H19 ko/p62 tg mice were significantly higher 
compared to H19 wt/p62 tg mice (Figure 2A, B).  
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Figure 2: Liver weight of female (left panels) and male (right panels) (A) untreated (co) and (B) DEN-
treated (DEN) mice (co n=10-23, DEN n=20-25). The p values were calculated by Mann-Whitney U test or 
ANOVA combined with Bonferroni post hoc test. 
 
 
Hence, the liver to body weight ratio revealed no significant alterations, neither for 
untreated nor for DEN-treated mice (Figure 3A, B).  
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Figure 3: Liver to body weight ratio of female (left panels) and male (right panels) (A) untreated (co) and 
(B) DEN-treated (DEN) mice (co n=10-23, DEN n=20-25). The p values were calculated by Mann-Whitney 
U test or ANOVA combined with Bonferroni post hoc test. 
 
 
H19 ko/p62 tg mice: gene expression 
 
To verify the effect of p62 on H19 expression in the H19 ko/p62 tg mouse model, qPCR 
experiments were performed. As expected (Tybl et al., 2011), p62 transgenic animals 
exhibited increased H19 expression in case of the H19 wild-type background. 
Furthermore, H19 expression was significantly upregulated after DEN treatment in H19 
wt/p62 wt animals (Figure 4A). 
Igf2 expression was increased in p62 transgenic compared to p62 wild-type female mice, 
while the transgenic p62 expression did not affect Igf2 expression in male mice (Figure 
4B). Female mice containing the H19 knockout revealed significantly increased Igf2 
expression after DEN treatment. The same tendency was found for male mice (Figure 
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4B). In comparison to respective wild-type mice, the H19 knockout did not affect Igf2 
expression except for male untreated p62 transgenic mice. 
 
 
 
Figure 4: (A) H19 and (B) Igf2 expression in livers of female (left panels) and male (right panels) untreated 
and DEN-treated mice determined by qPCR (co n=10-23, DEN n=20-25). n.a. = not available. The p values 
were calculated by Mann-Whitney U test. 
 
 
H19 ko/p62 tg mice: steatosis and fibrosis 
 
Steatosis is the first hit of liver disease (Day & James, 1998) and its development is 
promoted by transgenic p62 expression in mice (Tybl et al., 2011). Histological analyses 
of hematoxylin-eosin (H&E) stained liver sections revealed that none of the female mice 
and only 2 male H19 ko/p62 tg control mice, one H19 wt/p62 wt male DEN-treated mouse, 
and one H19 ko/p62 wt male control mouse developed macrovesicular hepatic steatosis 
(Figure 5).   
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Figure 5: Steatosis development. H&E staining of a male DEN-treated H19 wt/p62 tg mouse is shown 
(the arrows indicate lipid accumulation). 
 
 
Fibrosis characterized by collagen accumulation is present in most types of chronic liver 
disease in humans (Friedman, 2003). Fibrosis development in the H19 wt/p62 tg mouse 
model was analyzed by Sirius Red staining. Neither male nor female mice showed hepatic 
fibrosis (Figure 6). 
 
 
Figure 6: Fibrosis detection. Representative Sirius Red staining is shown. 
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H19 ko/p62 tg mice: tumor induction and characterization 
 
To clarify whether H19 has tumor-suppressive effects in the p62 transgenic mouse model, 
tumor development was investigated. 
First, the tumor promoting action of p62 as shown by Kessler et al. 2015 in 
DBA2J/C57BL/6J mice was confirmed in mice on a 129sv/DBA2J/C57BL/6J background 
(Kessler et al., 2015): more tumors were found in male DEN-treated than female DEN-
treated mice (Figure 7A). This is due to inhibitory effects of estrogens and stimulating 
effects of androgens on hepatocarcinogenesis (Nakatani et al., 2001, Naugler et al., 
2007). No tumors were found in untreated mice. H19 ko/p62 wt mice developed 
significantly more tumors than H19 wt/p62 wt mice in both sexes. This tumor-suppressive 
effect of H19 was not significant for mice with transgenic p62 expression (female p=0.70, 
male p=0.81) (Figure 7A). 
Small cell changes (SCCs) and large cell changes (LCCs) are dysplastic lesions found in 
the process of liver carcinogenesis (Park, 2011). Tumors of H19 ko/p62 wt mice displayed 
significantly more SCCs than tumors of H19 wt/p62 wt mice. Mice with transgenic p62 
expression showed also significantly more SCCs when they were H19 deficient (female 
p=0.62, male p<1E-8). Most SCCs were detected in tumors of male H19 ko/p62 tg mice, 
which also exhibited LCCs (Figure 7B). 
Taken together, the combination of p62 overexpression and lack of H19 did not 
significantly increase the number of tumors, but increased the dysplasia of tumor cells. 
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Figure 7: Tumor development and characterization in female (left panels) and male (right panels) DEN-
treated mice. (A) Tumor development and (B) predominant cell size in tumors of DEN-treated female and 
male mice (co n=10-23, DEN n=20-25). The p values were calculated by Chi-square test. 
 
 
Immunohistological stainings of all liver tumors revealed the expression of the tumor 
specific surface antigen Gp73 (Figure 8A). The early HCC marker glutamine synthetase 
(GS) was not expressed except for one male H19 wt/p62 tg and one male H19 ko/p62 tg 
mouse (Figure 8B).   
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Figure 8: Immunohistological staining of HCC markers. Representative (A) Gp73 and (B) GS stains 
(the arrows indicate GS positive brown stained cells) are shown. 
 
 
Further, tumors of male DEN-treated mice were analyzed with respect to the expression 
of the proliferation marker Ki67. Significantly more tumors of H19 ko mice expressed Ki67 
compared to H19 wt mice either with or without the p62 transgenic background (Figure 
9A, B). 
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Figure 9: (A) Expression of the proliferation marker Ki67 in tumors of male DEN-treated mice (score 
0: no proliferating cells detectable; score 1: less than 1% proliferating cells). The p values were calculated 
by Chi-square test. (B) Representative immunohistological staining of Ki67 (the arrows indicate Ki67 positive 
brown stained nuclei) (H19 wt/p62 wt n=9, H19 wt/p62 tg n=9, H19 ko/p62 wt n=10, H19 ko/p62 tg n=8). 
 
 
In summary, the hypothesized synergistic effects of transgenic p62 and lack of H19 
expression with respect to tumor development were not significant. These data suggest 
that H19 did not protect from the formation of tumors in p62 transgenic mice. However, 
the H19 knockout promoted tumor progression as well as tumor cell dysplasia and 
proliferation in p62 wild-type mice.  
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H19 ko/p62 tg mice: apoptosis 
 
The defective apoptosis pathway has been associated with the promotion stage of HCC 
(Guicciardi & Gores, 2005). An anti-apoptotic action of p62 in hepatoma cells treated with 
chemotherapeutics has been reported (Kessler et al., 2013). The role of H19 in apoptosis 
is conflicting: H19 knockout has been associated with reduced apoptosis in 
choriocarcinoma (Yu et al., 2013) as well as increased apoptosis in gastric cancer (Yang 
et al., 2012). 
The amount of apoptotic cells in p62 transgenic and H19 knockout mouse livers was 
analyzed by histological examination. An anti-apoptotic effect of p62 could not be 
determined. In fact, mice with transgenic p62 expression exhibited a higher amount of 
apoptotic cells (Figure 10A, B). H19 knockouts showed higher apoptosis induction in 
livers of untreated p62 wild-type mice (Figure 10A). The amount of apoptotic cells was 
not altered in livers of female DEN-treated mice, whereas in livers of male DEN-treated 
mice the H19 knockout significantly induced apoptosis (Figure 10B). These data rather 
suggest an anti-apoptotic effect of H19 in our model.  
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Figure 10: Apoptosis induction in livers of female (left panels) and male (right panels) (A) untreated (co) 
and (B) DEN-treated (DEN) mice (co n=10-23, DEN n=20-25) (score 0: no apoptotic cells found; score 1: 
less than 2 apoptotic cells in a 200x magnification; score 2: 2-4 apoptotic cells in a 200x magnification). The 
p values were calculated by Chi-square test.  
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H19 ko/p62 tg mice: inflammation 
 
Since inflammation is an important hallmark of cancer (Hanahan & Weinberg, 2011) and 
the role of H19 in this process is controversially discussed (Chen et al., 2016, Li et al., 
2016), the effect of H19 knockout on inflammation was analyzed by histological 
examination.  
In general, livers of female mice showed more lymphocytic and granulocytic infiltrates 
compared to livers of male mice (Figure 11A, B; 12A, B).  
In the group of untreated mice H19 knockout caused a significantly higher amount of 
inflammatory infiltrates (Figure 11A, 12A, 13). In female mice, also transgenic p62 
expression increased inflammation. Hence, the highest degree of inflammatory infiltrates 
was detected in female H19 ko/p62 tg mice (Figure 11A, 12A).  
H19 knockout did not clearly affect inflammation in livers of DEN-treated mice (Figure 
11B, 12B).  
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Figure 11: Lobular lymphocytic inflammation in livers of female (left panels) and male (right panels) (A) 
untreated (co) and (B) DEN-treated (DEN) mice (score 1: less than 2 lymphocytic cells in a 200x 
magnification; score 2: 2-4 lymphocytic cells in a 200x magnification) (co n=10-23, DEN n=20-25). The p 
values were calculated by Chi-square test.  
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Figure 12: Lobular granulocytic inflammation in livers of female (left panels) and male (right panels) (A) 
untreated (co) and (B) DEN-treated (DEN) mice (few = 1-5 neutrophil granulocytes per inflammatory 
infiltrate; many = more than 5 neutrophil granulocytes per inflammatory infiltrate) (co n=10-23, DEN n=20-
25). The p values were calculated by Chi-square test. 
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Figure 13: Inflammation in livers of female mice. Representative H&E stains of untreated mice are shown 
(arrows indicate inflammatory infiltrates).  
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Discussion 
 
Experimental mouse models are widely used in hepatocellular carcinoma research and 
accounted for the current state of knowledge on hepatocarcinogenesis and tumor 
progression (Heindryckx et al., 2009). The p62 transgenic mouse model on a 
DBA2J/C57BL/6J background has been well described with respect to steatosis, 
steatohepatitis, and fibrosis (Kessler et al., 2013, Laggai et al., 2014, Simon et al., 2014a, 
Simon et al., 2014b, Tybl et al., 2011). Steatohepatitis and fibrosis are amplified under 
transgenic p62 expression in respective models, but tumor development was only 
detected after induction by the carcinogen DEN (Kessler et al., 2015). Since the mouse 
strain has an impact on hepatocarcinogenesis (Heindryckx et al., 2009), tumor 
development in our p62 transgenic mice with a different genetic background 
(129sv/DBA2J/C57BL/6J) was analyzed. The tumor-promoting effect of p62 in mice 
treated with DEN as well as the lack of tumor development in p62 transgenic mice without 
tumor induction by DEN were confirmed on a 129sv/DBA2J/C57BL/6J background. 
Regarding the tumor phenotype, our results fit to the described characteristics (Kessler et 
al., 2015): the tumor marker Gp73 was detected as positive in all tumors, whereas GS 
was mostly negative with only two tumors of male p62 transgenic mice positively tested 
for both HCC markers. 
The influence of p62 on inflammation by increasing ROS generation has recently been 
described in hepatoma cells (Kessler et al., 2015). The significantly elevated amount of 
inflammatory infiltrates in female p62 transgenic mice confirmed the inflammation-
promoting action of p62. 
The crossing of p62 transgenic with H19 knockout mice was performed in order to 
elucidate the role of H19 in the validated tumor-promoting action of p62. The first 
distinctive feature of our H19 knockout mice was an elevated body weight (11.5% higher 
compared to wild-type mice). These results fit to the previously reported weight increase 
of H19 knockout mice (Ripoche et al., 1997). The weight gaining effect was suggested to 
be caused by the regulatory function of H19 in an imprinted gene network consisting of 
growth control genes (Gabory et al., 2009, Varrault et al., 2006). 
The role of H19 in carcinogenesis is controversely discussed. Although some researchers 
reported oncogenic properties of H19 (Barsyte-Lovejoy et al., 2006, Berteaux et al., 2005, 
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Matouk et al., 2007), a tumor-suppressive effect of H19 has been described in murine 
models of colorectal cancer, teratocarcinoma, and SV40-induced hepatocarcinoma 
(Yoshimizu et al., 2008). Our data support the tumor-suppressive function of H19: the H19 
knockout promoted DEN-triggered tumor development, tumor cell dysplasia, and tumor 
cell proliferation. In contrast to our hypothesis, H19 ko/p62 tg mice did not show the 
strongest tumor induction. This could be possibly explained by the following 
circumstances: Expression data from Laggai 2014 revealed a significantly downregulated 
H19 expression in p62 transgenic mice after DEN-treatment comparable to the conditions 
of our study (Laggai, 2014). In contrast, H19 expression is significantly elevated after 
DEN-treatment in p62 wild-type mice. Thus, the H19 knockout has a stronger impact in 
p62 wild-type than in p62 transgenic mice and this could be responsible for the missing 
additive effect of transgenic p62 and lack of H19 expression on tumor development. 
The H19 knockout stimulated p62-independent inflammation in mouse livers. Li et al. also 
reported an anti-inflammatory effect of H19 (Li et al., 2016), employing an H19 
overexpressing rat model. Since inflammation is an important carcinogenesis-inducing 
factor (Hanahan & Weinberg, 2011), the anti-inflammatory action of H19 further underlines 
its tumor-preventing potential. 
Taken together, the hypothesized tumor-protective function of H19 in p62 transgenic mice 
was not significant. However, some tumor characteristics of H19 ko/p62 tg mice - e.g. 
tumor cell dysplasia - were shifted towards the direction of a more advanced tumor state 
suggesting an inhibitory effect of H19 on tumor progression. 
The impact of H19 was mostly independent of transgenic p62 expression. Our data 
indicate a tumor-suppressive, anti-proliferative, and anti-inflammatory action of H19 and 
thereby underline its important role in initiation and progression of HCC. 
 
 
Part of the data concerning p62 wild-type mice were published in: Schultheiss C.S., 
Laggai S., Czepukojc B., Hussein U.K., List M., Barghash A., Tierling S., Hosseini K., 
Golob-Schwarzl N., Pokorny J., Hachenthal N., Schulz M., Helms V., Walter J., Zimmer 
V., Lammert F., Bohle R.M., Dandolo L., Haybaeck J., Kiemer A.K., and Kessler S.M. 
(2017) The long non-coding RNA H19 suppresses carcinogenesis and chemoresistance 
in hepatocellular carcinoma. Cell Stress. 1(1), 37-54.  
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The long non-coding RNA H19 suppresses carcinogenesis and 
chemoresistance in hepatocellular carcinoma  
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Introduction 
 
Non-coding sequences constitute the considerably larger part of the transcribed human 
genome compared to coding sequences since only 2% of the genome encode for proteins 
(International Human Genome Sequencing Consortium 2004).  
Recently, RNA-seq datasets were used to identify lncRNAs aberrantly expressed under 
inflammatory conditions. The well-described lncRNA H19 (long intergenic non-protein 
coding RNA 8), a maternally expressed imprinted gene product, was the lncRNA with the 
most consistent overexpression among all conditions investigated (Wang et al., 2016c). 
Since cholangiocarcinoma represents a tumor type that develops under inflammatory 
conditions and in settings of oxidative stress, the authors investigated the role of H19 in 
cholangiocarcinoma cell lines and observed tumor-promoting and pro-inflammatory 
actions of H19 (Wang et al., 2016c). In contrast, H19 was found to have tumor-
suppressing abilities in colorectal cancer, another inflammation-associated tumor entity 
(Ohtsuka et al., 2016), and the role of H19 in inflammation is conflicting (Chen et al., 2016, 
Li et al., 2016). 
Embedded in H19's first exon is the microRNA miR-675 (Cai & Cullen, 2007), the 
processing of which is negatively regulated by the RBP ELAV like RNA-binding protein 1 
(ELAVL1 / HuR) (Keniry et al., 2012), and has also been reported to affect cancer (Raveh 
et al., 2015) and inflammation (Chen et al., 2016, Kohno et al., 2014, Li et al., 2016, Lu et 
al., 2012). 
Also HCC evolves in an environment governed by metabolic and inflammatory stress as 
found in chronic viral hepatitis, as well as in alcoholic and non-alcoholic steatohepatitis 
(El-Serag & Rudolph, 2007). HCC represents the second most common cause of cancer-
related death worldwide (Stewart & Wild, 2014), which is not least due to its high 
chemoresistance. However, the role of H19 in HCC development, progression, and 
chemoresistance is still unclear. While Yoshimizu et al. reported accelerated tumor 
development in H19 knockout mice in SV40-induced HCC (Yoshimizu et al., 2008), 
Matouk et al. observed an enhanced tumorigenic potential of carcinoma cells in vivo upon 
ectopic H19 expression (Matouk et al., 2007). Allelic expression of H19 is controlled by 
an imprinting control region and by a promoter, which can be differentially methylated 
(Gabory et al., 2006). Loss of imprinting (LOI), i.e. biallelic H19 expression, was reported 
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for HCC using small sample size cohorts (Kim & Lee, 1997, Wu et al., 2008). In general, 
human data on H19 expression in HCC should be interpreted with caution because the 
number of samples available for the studies dealing with this topic was mostly rather small 
(Kim & Lee, 1997, Wu et al., 2008). 
We therefore conducted comprehensive studies using four independent patient cohorts, 
H19 knockout mice, and three different human hepatoma cell lines to decipher the role of 
H19 in HCC development, hepatoma cell growth, and chemoresistance. 
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Results 
 
Based on recent reports suggesting H19 as an inflammation-inducible lncRNA and HCC 
representing a disease developing in an inflammatory environment, we sought to 
determine H19 expression in human HCC. The comparison of n=364 HCC tissues with 
n=49 normal liver tissues from TCGA sequencing data revealed highest H19 expression 
in a subgroup of HCC samples. Still, statistical analysis of all samples showed an allover 
decreased expression of H19 in HCC tissues (Figure 1A). Comparing H19 expression of 
HCC tissues only to their respective adjacent tissues, H19 expression was still decreased 
with high statistical significance (data not shown, p=5.28E-7). Also analysis of two 
microarray GEO datasets with n=39/39 (GSE57957) and n=74/74 (GSE54236) HCC 
tissues vs. non-tumor tissues revealed a distinct downregulation of H19 (Figure 1B and 
C) as did qPCR quantification of H19 in a previously described patient cohort (Figure 1D) 
(Kessler et al., 2013, Kessler et al., 2014). In situ hybridization against H19 revealed low 
expression of H19 in tumor tissues, but higher expression in the non-tumorous tissues 
adjacent to the tumor site in an additional patient cohort (Figure 1E). All cohorts 
comprised patients with HCC from different etiologies. Q-PCR of hepatocytes, 
microdissected from the small subgroup of HCC samples showing high H19 expression 
(Figure 1D) suggested that H19 was in fact overexpressed in hepatocytes (Figure S2). 
Chapter 3 
43 
 
 
Figure 1: H19 expression in human HCC tissues (tumor) compared to non-tumorous tissues (non-tumor). 
(A) Log2 H19 expression in HCC tissues from TCGA dataset (non-tumor: n=49, tumor: n=364, Mann-
Whitney U test). (B) Log2 H19 expression in HCC tissues from GEO dataset GSE57957 (each, n=39, 
Kolmogorov-Smirnov test). (C) Log2 H19 expression in HCC tissues from GEO dataset GSE54236 (each, 
n=74, Kolmogorov-Smirnov test). (D) H19 expression in HCC tissues from Saarland University Medical 
Center determined by qPCR (each, n=32, Mann-Whitney U test). (E) Representative chromogenic in situ 
hybridization (CISH) of H19 (H19 positive cells: brown; H19 negative cells: red) (each, n=8). 
 
 
In accordance with the results from H19 expression, which encodes miR-675, the more 
abundant miR-675-3p was downregulated in HCC (Figure 2A) and strongly correlated 
with H19 (R²=0.91, p<1.0E-15). The less abundant miR-675-5p was not detectable in most 
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samples. The RBP HuR/ELAVL1 has been shown to represent a negative regulator of 
miR-675 processing in the mouse system by binding to H19 (Keniry et al., 2012). 
Interestingly, expression of ELAVL1 was significantly upregulated in HCC (Figure 2B) 
suggesting an inhibited processing of H19 into miR-675. RNA immunoprecipitation (RIP) 
experiments in Huh7 cells confirmed that HuR/ELAVL1 also binds to human H19: H19 
was significantly enriched in HuR immunoprecipitates over the negative control GAPDH 
(Figure 2C). Also the positive control CCNB1 showed a significantly enriched binding 
compared to the negative control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: miR-675 and ELAVL1/HuR expression in human HCC tissues (tumor) compared to non-
tumorous tissues (non-tumor). (A) Log2 miR-675-3p expression and (B) Log2 ELAVL1 expression in HCC 
tissues from the TCGA dataset (non-tumor: n=49, tumor: n=364, Mann-Whitney U test). (C) RIP was 
performed using either IgG or an HuR antibody. Co-precipitated mRNAs H19; CCNB1, as a positive control; 
GAPDH, as a negative control; were determined by qPCR (n=3, duplicates). Data show x-fold enrichment 
over the levels found in IgG immunoprecipitates. 
 
 
The data from independent patient cohorts showed a clear downregulation of H19 in HCC 
as a strongly inflammation-associated tumor type. This is why we investigated whether 
H19 expression is in fact downregulated due to an inflammatory reaction. In fact, we found 
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 promoter methylation GSE57956 
a downregulation of H19 in mice treated with the inflammation-inducing carcinogen DEN 
(n=5, 0.11 fold ± 0.04, p=0.0508, two-sample t-test).  
Since H19`s expression is epigenetically controlled and LOI of H19 has been found in 
some tumor types, we determined allelic expression of H19 in human HCC by RFLP 
analysis employing the 32 samples from our patient cohort (Figure 1D). The experiment 
showed that nine of the patients were heterozygous and therefore informative for RFLP 
analysis (Figure 3A). LOI was observed in three normal as well as in three tumor tissues 
while the other tissues showed monoallelic expression (Figure 3A). These findings 
suggest that LOI is not involved in the deregulation of H19 expression in HCC. 
Besides its regulation by imprinting mechanisms H19 expression is also distinctly 
regulated by the extent of its promoter methylation (Gao et al., 2002, Hadji et al., 2016). 
Thus, we analyzed the HCC methylation dataset GSE57956 regarding H19 promoter 
methylation. This dataset also comprises the 39 samples for which H19 expression was 
already determined (GSE57957, Figure 1B). The analysis revealed a distinctly decreased 
H19 promoter methylation with high statistical significance in HCC vs. normal tissues 
(Figure 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Epigenetic state of the H19 locus in human HCC tissues (tumor) and non-tumorous tissues 
(non-tumor). (A) LOI was analyzed by RFLP analysis of 9 informative gDNA samples. Representative 
agarose gel with gDNA and cDNA before (left) and after digestion with the restriction enzyme AluI (right). 
(B) H19 promoter methylation represented as fractional β-values from GEO dataset GSE57956 (each, n=58, 
Kolmogorov-Smirnov test). 
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Due to the downregulation of H19 in HCC we aimed to determine functional aspects of 
H19 overexpression in liver cancer cells. Thus, the colony formation assay - a well 
established method to determine in a cell population every cell’s ability to undergo 
unlimited division (Franken et al., 2006) - was performed in three different stably H19 
overexpressing human hepatoma cell lines. All three cell lines we investigated, i.e. 
HepG2, Plc/Prf/5, and Huh7, showed that H19 suppresses tumor cell survival, as indicated 
by a reduced colony number (Figure 4A-D). 
To explore the potential role of H19 in chemosensitivity, the three stably H19 
overexpressing cell lines were treated with either sorafenib or doxorubicin, two 
therapeutics which have clinically been tested for HCC treatment (Germano & Daniele, 
2014, Lencioni et al., 2016). All stably H19 overexpressing cell lines showed significantly 
increased sensitivity in the clonogenicity assay, suggesting a chemotherapy-sensitizing 
action of H19 (Figure 4A-D). In order to distinguish reduced colony formation from 
chemosensitizing actions of H19, we also performed a different data normalization 
strategy, which can be found as supplemental Figure S3. Also this quantification 
confirmed a chemosensitizing action of H19.   
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Figure 4: Effect of H19 overexpression on colony formation ability in stably H19 overexpressing (H19) 
and vector control (control, co) HepG2 (left panels), Plc/Prf/5 (middle panels), and Huh7 (right panels) cells. 
(A, C) Representative results of clonogenicity assays using untreated and (A) doxorubicin or (C) sorafenib 
treated hepatoma cells. (B, D) Colony formation ability of H19 overexpressing cells normalized to their 
respective untreated control cells after (B) doxorubicin (n≥3, duplicates) or (D) sorafenib (n=3, triplicates) 
treatment. The p values were calculated by two-sample t-test or Mann-Whitney U test depending on the 
data distribution. * p < 0.05, ** p < 0.01, *** p < 0.001.  
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miR-675 is unlikely to be responsible for this action: while H19 expression was significantly 
upregulated up to 65-fold ± 9.4 in stably transfected cells (n=3, triplicates, p=2.4E-6, two-
sample t-test), two of the three cell lines showed no increase in miR-675 expression (n=3, 
triplicates, each: HepG2: 9.2-fold ± 7.3, p=0.06, Mann-Whitney U; Huh7: 1.7-fold ± 1.0, 
p=0.36, Mann-Whitney U). Only stably H19 overexpressing Plc/Prf/5 cells revealed slightly 
upregulated miR-675 expression (n=3, triplicates, 1.5-fold ± 0.17, p=1.2E-3, two-sample 
t-test), while H19 was 6.9-fold higher expressed (n=3, triplicates, 10.3-fold ± 2.3, p=1E-4). 
Concordantly, ELAVL1 mRNA levels were not affected in all three cell lines upon H19 
overexpression (data not shown). In HepG2 and Huh7, the action was independent of the 
anti-apoptotic growth factor IGF2 (Kessler et al., 2013), frequently regulated in parallel 
with H19 due to the genomic vicinity and shared imprinting control region (Rachmilewitz 
et al., 1992): IGF2 expression was unchanged in both stably H19 overexpressing cell lines 
compared to empty vector-transfected controls (n=3, triplicates, each: HepG2: 1.4-fold ± 
0.6, p=0.16, Mann-Whitney U test; Huh7: 1.1-fold ± 0.1, p=0.17, two-sample t-test). Still, 
in Plc/Prf/5 the expression of IGF2 was significantly downregulated (n=3, triplicates, 0.3-
fold ± 0.1, p=3.9E-6, two-sample t-test). Interestingly, Plc/Prf/5 exhibited a highly 
increased intrinsic chemoresistance compared to the other two cell lines. 
In order to determine whether H19 overexpression or knockdown directly affected 
cytotoxicity, cell viability was measured by MTT assay either in stably H19 overexpressing 
cells or in cells with a gapmer-facilitated H19 knockdown upon treatment with the cytotoxic 
agent doxorubicin. Cell viability with overexpressed or knocked down H19 was largely 
unchanged in Plc/Prf/5 and Huh7 cells, although a few values reached statistical 
significance (Figure 5A, B). Only in H19 gapmer-treated HepG2 cell viability was distinctly 
elevated compared to gapmer control cells (Figure 5B). These heterogenous findings 
suggested that H19-facilitated chemosensitization in Plc/Prf/5 and Huh7 is unlikely to 
depend on altered cell death but might rather depend on reduced proliferative capacity. 
Therefore, proliferation measurements in H19 overexpressing cells by Ki67 staining and 
subsequent FACS quantification were performed. Interestingly, while proliferation of 
HepG2 cells was unchanged in H19 overexpressing cells, H19 exhibited a significant 
proliferation-suppressing activity in Plc/Prf/5 and Huh7 cells (Figure 5C).  
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Figure 5: Effect of H19 overexpression and knockdown on cell viability and proliferation in HepG2 
(left panels), Plc/Prf/5 (middle panels), and Huh7 (right panels) cells. (A) Cytotoxicity assay with doxorubicin 
in stably H19 overexpressing (H19) or vector control (control) cells normalized to their respective untreated 
control (n=2, sextuplicates). (B) Cytotoxicity assay with doxorubicin after transfection with H19 gapmer (H19 
knockdown) and control gapmer (control) normalized to their respective untreated control (n=2, 
sextuplicates). (C) FACS analysis of the proliferation marker Ki67 in stably H19 overexpressing (H19) and 
vector control cells (control). Representative histograms of Ki67 FACS analysis are shown (upper panels). 
Quantification of Ki67 positive cells expressed as percent of control (n≥2, triplicates). The p values were 
calculated by two-sample t-test or Mann-Whitney U test depending on the data distribution. * p < 0.05, ** p 
< 0.01, *** p < 0.001.  
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We hypothesized that a downregulation of H19 might also contribute to chemoresistance 
as induced by repeated treatment with chemotherapeutics. To test this hypothesis, we 
established doxorubicin- and sorafenib-resistant HepG2, Plc/Prf/5, and Huh7 cell lines by 
repeated treatment with the drugs. Their chemoresistance was confirmed by directly 
comparing their sensitivity with non-resistant cells towards the drugs in a dose-response 
analysis (Figure 6A, B). 
Quantifying H19 expression by qPCR revealed that chemoresistance was associated with 
strongly downregulated H19 expression in doxorubicin resistant cells (Figure 6C). 
However, miR-675 was not significantly affected in any of the doxorubicin resistant cells 
(n=2, duplicates, each: HepG2-Dox-R: 0.52-fold ± 0.30, p=0.11, two-sample t-test; 
Plc/Prf/5-Dox-R: 0.71-fold ± 0.25, p=0.20, two-sample t-test; Huh7-Dox-R: 2.13-fold ± 0.86 
p=0.16, two-sample t-test). Also in sorafenib resistant cell lines H19 expression was 
significantly suppressed (Figure 6C). 
Analysis of the multidrug resistance protein 1 (MDR1, ABCB1) showed increased 
expression in all doxorubicin (n=2, duplicates, each: HepG2-Dox-R: 44.2-fold ± 8.8, 
p=6.2E-3, two-sample t-test; Plc/Prf/5-Dox-R: 1.8-fold ± 0.2, p=3.1E-2, Mann Whitney U 
test; Huh7-Dox-R: 6.7-fold ± 0.4, p=2.3E-4, two-sample t-test) and sorafenib resistant 
(n=3, triplicates, each: HepG2-Sora-R: 4.1-fold ± 0.7, p=4.5E-5, two-sample t-test; Huh7-
Sora-R: 1.5-fold ± 0.2, p=3.4E-4, two-sample t-test) cell lines except for sorafenib resistant 
Plc/Prf/5 cells (n=3, triplicates, Plc/Prf/5-Sora-R: 0.6-fold ± 0.1, p=2.8E-6, two-sample t-
test).  
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Figure 6: Validation of chemoresistance and expression of H19 in sorafenib resistant (Sora-R), 
doxorubicin resistant (Dox-R), and chemosensitive (control) HepG2 (left panels), Plc/Prf/5 (middle panels), 
and Huh7 (right panels) cells. (A, B) Cytotoxicity assay normalized to the respective untreated control in (A) 
doxorubicin resistant cells (n=2, quintuplicates) and (B) sorafenib resistant cells (n=3, quintuplicates). (C) 
H19 expression determined by qPCR in doxorubicin (n=3, duplicates) and sorafenib (n=3, triplicates) 
resistant cells normalized to control cells. The p values were calculated by two-sample t-test or Mann-
Whitney U test depending on the data distribution. * p < 0.05, ** p < 0.01, *** p < 0.001. 
 
 
To elucidate if altered promoter methylation is again linked to changed H19 expression, 
the H19 promoter methylation status was analyzed by local deep bisulfite sequencing (Bi-
PROF) covering 23 CpG sites (Figure 7A) in the six chemoresistant cell lines. All three 
cell lines resistant for sorafenib showed elevated CpG methylation compared to their 
sensitive counterparts (Figure 7C): in Plc/Prf/5 cells 18 out of 23 investigated CpGs 
showed an elevated methylation; in HepG2 only five CpGs were hypermethylated (with 
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two hypomethylated), while most CpGs were hypermethylated in Huh7 cells. Almost all 
investigated CpGs in Huh7 also showed an elevated methylation in doxorubicin 
resistance. Interestingly, though, almost half of the CpGs were hypomethylated in 
doxorubicin resistant Plc/Prf/5 cells and an almost equal number of CpGs was hyper- or 
hypomethylated in doxorubicin resistant HepG2 (three up, four down) (Figure 7B). Taken 
together, although only Huh7 cells showed a consistent distinct hypermethylation, all three 
cell lines altered the methylation state of the H19 promoter during chemoresistance. Most 
differences were found at CpG sites close to the transcription start site of H19 (Figure 7A-
C). Since these findings were highly reproducible in three independent biological 
replicates and similar to deregulated promoter methylation in HCC samples, we 
suggested an involvement of a deregulated promoter methylation in suppressed H19 
expression during chemoresistance.   
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Figure 7: Methylation state of the H19 promoter in chemoresistant cells. (A) Analyzed H19 promoter 
region. The bisulphite-converted DNA sequence is shown; CpG sites 1-23 (Chr.11: 2,019,761 - 2,019,488) 
are labelled in grey; amplification primers are underlined. (B, C) Absolute methylation of 23 CpG sites 
located in the H19 promoter in chemoresistent (resistant) and chemosensitive (control) HepG2 (upper 
panels), Plc/Prf/5 (middle panels), and Huh7 (bottom panels) cells analyzed by Bi-PROF (n=3, triplicates). 
(B) Doxorubicin resistant and (C) sorafenib resistant hepatoma cells. The p values were calculated by two-
sample t-test or Mann-Whitney U test depending on the data distribution. * p < 0.05, ** p < 0.01, *** p < 
0.001.  
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Therefore, we tested whether 5-azacytidine, a DNA demethylating agent, had an effect 
on chemosensitivity. As expected, the compound altered the CpG methylation of the H19 
promoter in two of the three cell lines as measured by SNuPE (Figure 8A) and 
significantly increased H19 expression in the same two cell lines (Figure 8B) with the 
strongest effect being seen in HepG2 cells, which were also distinctly sensitized towards 
doxorubicin in the presence of 5-azacytidine (Figure 8C). This is why HepG2 cells were 
also employed for an approach to test whether H19 overexpression can reverse 
chemoresistance. We in fact observed an increased induction of cell death by doxorubicin 
after transfecting chemoresistant cells with H19 (Figure 8D). Since H19 rather seemed to 
act on proliferative actions in Huh7, we overexpressed H19 in chemoresistant Huh7 cells 
and in fact also observed chemosensitization (Figure 8E).  
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Figure 8: Methylation dependent H19 expression and its effect on cell viability and proliferation. (A-
C) HepG2 (left panels), Plc/Prf/5 (middle panels), and Huh7 cells (right panels) treated with 5-azacytidine 
(5-aza) and untreated control cells (control) were analyzed for (A) methylation index of two CpG sites of the 
H19 promoter by SNuPE (n=2, duplicates), (B) H19 expression determined by qPCR (n=2, duplicates), and 
(C) viability after treatment with doxorubicin by cytotoxicity assay (n=2, quintuplicates). (D) Cytotoxicity 
estimated by MTT assay after treatment with doxorubicin in doxorubicin resistant HepG2 either transiently 
overexpressing H19 (H19) or vector control transfected (control) for 48 h normalized to the respective 
untreated control (n=2, triplicates). (E) Quantification of Ki67 positive cells by FACS in sorafenib resistant 
Huh7 either transiently overexpressing H19 (H19) or vector control transfected (control) for 48 h and 
expressed as percent of control (each, n≥2, duplicates). The p values were calculated by two-sample t-test 
or Mann-Whitney U test depending on the data distribution. * p < 0.05, ** p < 0.01, *** p < 0.001. 
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The data on reduced expression of H19 in human HCC and its chemosensitizing actions 
suggested tumor-suppressive actions of H19 in HCC. To determine whether the presence 
of H19 has an impact on tumorigenesis, wild-type and H19 knockout animals were treated 
with the carcinogen DEN for 24 weeks. As expected (Nakatani et al., 2001), male mice 
developed more tumors than female mice (Figure 9A). In both sexes, H19 knockout 
significantly increased the number of solid tumors. Trabecular tumors were only 
detectable in male H19 knockout mice. The histological analysis also indicated that tumors 
of DEN-treated H19 deficient mice were characterized by small cell changes representing 
dysplastic lesions found in the process of liver carcinogenesis (Figure 9B).  
The proliferation-suppressive actions of H19, as shown in the two human hepatoma cell 
lines Huh7 and Plc/Prf/5, could also be verified in vivo: H19 deficient long-term DEN-
treated animals exhibited elevated Ki67 staining (Figure 9C). The expression of the 
oncogenic growth factor Igf2 was not different between wild-type and H19 knockout mice 
(Figure 9D), although Igf2 expression was significantly induced upon DEN treatment in 
H19 knockouts (Figure 9D).  
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Figure 9: Tumor development and characterization in long-term DEN-treated H19 knockout (H19 ko) 
compared to H19 wild-type (H19 wt) mice. (A) Tumor development in female (left) and male (right) DEN-
treated mice (female: H19 wt n=22, H19 ko n=25; male: H19 wt n=25, H19 ko n=20). (B) Predominant cell 
size in tumors of DEN-treated female (left) and male (right) mice. (C) Representative immunohistological 
staining of proliferation marker Ki67 (left, score 0: no proliferating cells detectable; score 1: less than 1% 
proliferating cells with brown stained nuclei (arrow)) and expression of Ki67 in tumors of male DEN-treated 
mice (right, H19 wt n=9, H19 ko n=10). (A-C) The p values were calculated by Chi-square test. * p < 0.05, 
** p < 0.01, *** p < 0.001. (D) Igf2 expression in female (left) and male (right) control (co) and DEN-treated 
(DEN) mice determined by qPCR (co n=10-23, DEN n=20-25). The p values were calculated by Mann-
Whitney U test. * p < 0.0125.  
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Discussion 
 
H19 was first described more than thirty years ago, at a time when the biological role of 
non-coding RNAs was still undefined (Pachnis et al., 1984). Since H19 together with Igf2 
and Igf2r belongs to the first imprinted genes described (Bartolomei et al., 1991, Tilghman 
et al., 1993), most of the first two decades of H19 research focused on its epigenetic 
regulation.  
While mouse data show a distinct downregulation of H19 expression in all tissues except 
for skeletal muscle after birth (Bartolomei et al., 1991), analysis of human samples shows 
well detectable H19 levels in a wide array of tissue types (see e.g. 
http://medicalgenome.kribb.re.kr/GENT/). In fact, our analyses of four different patient 
cohorts comprising several hundreds of samples showed significantly higher H19 
expression in normal liver tissue compared to HCC tissue. These findings support the 
findings of a previous study that analyzed H19 expression in 33 HCC tissues by qPCR 
compared to either adjacent non-tumor tissue or remote relative normal tissue (Zhang et 
al., 2013). As in our results, some HCC tissues of that study showed a dramatic increase 
in H19 expression, but altogether H19 was downregulated in HCC with high statistical 
significance. In fact, H19 expression was significantly lower in invasive HCC samples 
(n=31) compared to non-invasive HCC tumors (n=41) (Zhang et al., 2013). 
Interestingly, other studies reported elevated H19 expression in HCC, e.g. Ariel et al., 
1998, Fellig et al., 2005, Sohda et al., 1998, Wu et al., 2008. It has to be noted, however, 
that these studies investigated a considerably lower number of samples and/or used 
methods, such as in situ hybridization with limited quantitative reliability. Taking into 
account that all of our four patient cohorts, as well those investigated by Zhang et al. 
(2013), contained a small HCC patient subcohort with very high H19 levels, it becomes 
clear that investigations of small patient cohorts can lead to contradictory findings. 
Also reports on a potential LOI, i.e. biallelic H19 expression, are of limited significance. In 
fact, some studies have reported LOI in a subset of HCC tissues ranging between 21% 
and 66%. The sample numbers of these studies, again, were very low (n=3 or n=23) (Kim 
& Lee, 1997, Wu et al., 2008). Our data revealed no difference in the imprinting status 
between normal and HCC tissue, with an equal proportion of samples exhibiting biallelic 
expression. 
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With the knowledge on a distinct regulation of H19 expression by epigenetic modifications, 
we focused on potential alterations in the methylation state of the H19 promoter. Indeed, 
we observed strongly altered H19 promoter methylation in human HCC vs. normal liver 
tissue. While decreased promoter methylation is typically thought to be linked to elevated 
gene expression (Kong et al., 2011, Okada et al., 2005, Yang et al., 2017), a 
hypermethylated promoter region has also been associated with increased expression of 
some genes (Ding et al., 2009, Wagner et al., 2014). In fact, our data from a large HCC 
patient cohort suggested reduced promoter methylation correlating with reduced gene 
expression. Since HCC and other cancer types are associated with global DNA 
hypomethylation (Kim et al., 1994, Lin et al., 2001, Shen et al., 1998), the link between 
H19 expression and promoter methylation remains unclear and should be clarified in 
further studies. We observed the same in the investigated doxorubicin resistant Plc/Prf/5 
cell line, which showed both reduced H19 expression and reduced promoter methylation 
compared to its chemosensitive counterpart. Interestingly, Plc/Prf/5 showed a much lower 
baseline promoter methylation compared to both HepG2 and Huh7 suggesting a 
differential epigenetic profile. Along this line, treatment of Plc/Prf/5 cells with the DNA 
demethylating agent 5-azacytidine neither affected H19 promoter methylation nor H19 
expression. 
All three sorafenib resistant cell lines as well as doxorubicin resistant Huh7 cells exhibited 
significantly elevated H19 promoter methylation and at the same time significantly 
reduced H19 expression compared to their respective chemosensitive counterparts. 
These findings are in line with anti-correlated methylation of the H19 promoter and 
expression of H19 as found by others (Gao et al., 2002, Hadji et al., 2016). Accordingly, 
treatment with the methyltransferase inhibitor 5-azacytidine reduced H19 promoter 
methylation in both HepG2 and Huh7 cells and significantly increased H19 expression, as 
previously observed in other cell types (Diesel et al., 2012). Interestingly, H19 itself has 
been reported to increase DNMT3B-mediated cytosine methylation (Zhou et al., 2015a), 
suggesting diverse feedback processes. 
Induction of H19 by 5-azacytidine in HepG2 and Huh7 cells increased their 
chemosensitivity. This confirms findings in the literature on chemosensitizing actions of 
the compound (Festuccia et al., 2009). Chemoresistant versions of all three investigated 
cell lines showed downregulated H19 expression. This suggested chemosensitizing 
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actions of H19. In fact, H19 overexpression sensitized all three tested cell lines against 
both sorafenib and doxorubicin in clonogenicity assays. This effect seems to result from 
a synergistic effect of H19’s anti-proliferative and chemosensitizing actions. These 
findings on chemosensitizing action of H19 are in contrast to a paper reporting 
chemoresistance induction by H19 and linking it to induction of the multidrug resistance 
protein (MDR1, ABCB1) (Tsang & Kwok, 2007). Our investigations employing three 
different hepatoma cell lines could not verify these effects. 
Chemosensitizing actions of H19 in our hands seemed to differ between the different cell 
lines: in HepG2 cells, modulation of H19 expression rather affected cell death, whereas 
in Huh7 cells, H19 suppressed proliferation. 
Our clonogenicity data suggest growth-suppressive actions of H19 in the absence of any 
drug treatment. These data corroborate a hypothesis on the role of maternally expressed 
genes in embryonic development, already formulated in the early 1990s (Moore & Haig, 
1991). It provided a model of parental conflict, in which the females, through maternally 
expressed genes, balance resources allocated to current and future offspring. This notion 
led to the anticipation that maternally expressed genes limit growth.  
Our in vivo data employing H19 knockout mice showed accelerated tumor development 
and more aggressive tumors. The literature contains two different H19 knockout mouse 
models. One of them, the H19Δ13 mouse, shows a distinct overgrowth phenotype 
(Leighton et al., 1995). This overgrowth is facilitated by a full re-expression of the adjacent 
Igf2 gene from the normally silent maternal allele due to the combined 13 kb deletion of 
the H19 gene and of the imprinting control region (Leighton et al., 1995). In the H19Δ3 
knockout model, which we used and which only carries a 3 kb deletion of the H19 gene, 
only a slight re-expression of the maternal Igf2 was detected in mesodermal tissue 
(Ripoche et al., 1997). With liver representing an endodermal tissue, Igf2 expression is 
not increased in H19Δ3 mice as previously reported (Ripoche et al., 1997) and confirmed 
by ourselves. 
In contrast to our findings Matouk et al. (2007) suggested tumor-promoting actions of H19 
in a xenograft model employing Hep3B cells. Different aspects might be responsible for 
this discrepancy. While our model involves in vivo tumor induction, a xenograft model 
employs established tumor cells. So tumor-inducing actions can not be investigated with 
a xenograft model. Another aspect relates to the role of the immune defense since tumor 
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growth and development are strongly controlled by the immune system and xenograft 
models employ immune deficient mice. In 2008, Yoshimizu and colleagues investigated 
the role of H19 and reported in fact that in vivo HCC development was accelerated in H19 
knockout mice (Yoshimizu et al., 2008).  
There are several papers that regard H19 as a promoter of cancer initiation and 
progression in a set of tumor types (Raveh et al., 2015). Interestingly, most of the H19 
actions in this context have been explained by miR-675, a microRNA embedded within 
H19. This microRNA targets a whole array of transcripts, such as Igf1r, Smad1, Smad5, 
Cdc6, CDH-11 and -13 , RB1, RUNX1, NOMO 1 , TGFBI, CALN1, and MITF (reviewed in 
Raveh et al., 2015) and promotes cell proliferation (Yu et al., 2016). In contrast, a recently 
published paper clearly showed that H19 reduces proliferation (Martinet et al., 2016).  
Taken together, the discrepancy of effects of H19 in the three different cell lines and the 
controversial literature data suggest a strong context dependency, and needs to be 
addressed in further studies.  
While the expression of H19 was always strongly affected in our chemoresistance and 
proliferation studies, miR-675 showed minimal expression alterations. This is why we 
assume that in HCC it is rather H19 than miR-675, which exerts biological actions. 
Interestingly, the RBP HuR/ELAVL1, which has immunoregulatory potential (e.g. 
Hoppstädter et al., 2016) and suppresses the processing of H19 into miR-675 (Keniry et 
al., 2012), is overexpressed in human HCC (Vazquez-Chantada et al., 2010, Zhu et al., 
2015), but not differentially expressed in our chemoresistant cell lines. In fact, tumor-
promoting actions by HuR/ELAVL1 via the inhibition of microRNA processing in HCC have 
recently been reported (Zhang et al., 2015). 
Taken together, despite a small patient subcohort showing overexpressed H19, the 
majority of HCC tissues contained significantly reduced levels of this epigenetically 
regulated lncRNA. With its effect on HCC cancer cell growth, chemosensitivity, and 
carcinogenesis, H19 shows tumor-suppressive actions. Restoring H19 actions might 
therefore represent an interesting approach for future HCC therapy.  
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These data were published in: Schultheiss C.S., Laggai S., Czepukojc B., Hussein U.K., 
List M., Barghash A., Tierling S., Hosseini K., Golob-Schwarzl N., Pokorny J., Hachenthal 
N., Schulz M., Helms V., Walter J., Zimmer V., Lammert F., Bohle R.M., Dandolo L., 
Haybaeck J., Kiemer A.K., and Kessler S.M. (2017) The long non-coding RNA H19 
suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma. Cell 
Stress. 1(1), 37-54.  
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H19 as a molecular sponge  
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Introduction 
 
Micro RNAs (miRNAs) are single-stranded, 18-24 nucleotides long molecules that 
typically facilitate the translational repression or degradation of mRNA transcripts 
achieved by base pairing (Ambros, 2004). A dysregulation of miRNAs is associated with 
numerous diseases including HCC (Vrijens et al., 2015). 
LncRNAs can act as molecular sponges or competing endogenous RNAs (ceRNA) to 
affect miRNA activity and thereby their target mRNA levels (Poliseno et al., 2010). In this 
way, ceRNAs exert strong regulatory control in so-called sponge or ceRNA networks. For 
H19, many interactions with miRNAs are already known, e.g. with the tumor-suppressive 
miRNAs let-7, miR-200b, and miR-200c (Kallen et al., 2013, Zhou et al., 2017), the 
proliferation associated miR-194 (Wang et al., 2016b), and miR-200a, miR-138, and miR-
141, which are involved in epithelial to mesenchymal transition (Liang et al., 2015, Zhou 
et al., 2015b). However, these previous studies about a sponge function of H19 did not 
represent its capacity in the biological regulatory network system, where most mRNAs 
contain binding sites for different miRNAs and the miRNAs target more than one mRNA. 
In this study we analyzed whether H19 acts as a ceRNA within a whole miRNA sponge 
network in HCC.  
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Results 
 
A novel method called sparse partial correlation on gene expression (SPONGE) was 
developed by the group of Dr. Marcel Schulz (Department for Computational Biology and 
Applied Algorithmics, Max Planck Institut for Informatics (MPI-I), Saarland University) to 
predict the potential targets of H19 in HCC progression (List et al., 2017). Figure 1A 
shows the generated H19 network: the top 27 mRNAs are predicted targets for 28 miRNAs 
with more than three interactions among the target genes (prediction was performed by 
Dr. Marcel Schulz and Dr. Markus List from the MPI-I). 14 out of the 267 H19 sponge 
targets were investigated by qPCR in stably H19 overexpressing HepG2 cells to confirm 
the prediction. While most predicted targets showed a tendency of higher expression, only 
H2AFY2, IKBKAP, NINL, and SMYD3 were significantly upregulated in H19 
overexpressing HepG2 compared to vector control cells. A significant downregulation was 
detected only for AFP, which was predicted to be a strong molecular sponge itself (Figure 
1B).  
The results of these experiments were essential for the assessment of the prediction 
quality of sensitivity correlation-based ceRNA interaction inference und fueled the 
development of a new version of SPONGE that takes several confounding factors into 
account, such as gene-gene correlation, which were neglected before. 
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Figure 1: Predicted H19 sponge genes. (A) Bioinformatically generated H19 network including 27 mRNAs 
and 28 miRNAs. (B) Gene expression analysis of predicted H19 sponge genes in H19 overexpressing cells 
normalized to vector control cells (n=3) determined by qPCR. The p values were calculated by two-sample 
t-test for DNMT3B, H2AFY2, IKBKAP, KDELC1, NINL, SLC15A1, SOAT2, and WASF1; and Mann-Whitney 
U test for AFP, BRCA1, CTSV, E2F8, MYBL2, and SMYD3.  
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Discussion  
 
The mRNA expression analyses of the predicted target genes in stably H19 
overexpressing cells validated the bioinformatical prediction: most of the analyzed H19 
targets were upregulated in stably H19 overexpressing cells, with four of them reaching 
statistical significance. The majority of predicted miRNAs and target mRNAs in the 
generated network has not been associated with H19 before. They include, for example, 
SMYD3 encoding a histone methyltransferase that activates cell-cycle associated genes 
(Hamamoto et al., 2004). The influence of H19 on genes facilitating epigenetic regulations 
is already known from the literature: in a complex together with methyl-CpG-binding 
protein domain 1 (MBD1) it interacts with histone lysine methyltransferases (Monnier et 
al., 2014). Further, Zhou et al. pointed out an interaction of H19 with the DNA 
methyltransferase DNMT3B through an S-adenosylhomocysteine hydrolase resulting in 
a genome-wide alteration of DNA methylation in embryonic cells (HEK-293) (Zhou et al., 
2015a). Our prediction also included DNMT3B as a target gene of H19, but the DNMT3B 
mRNA level was not significantly altered in stably H19 overexpressing cells. Still, our 
results fit to the hypothesis that H19 partly exerts its function by affecting genes involved 
in epigenetic processes. 
The predicted targets further include H2AFY2 and BRCA1, two genes encoding tumor 
suppressors (Bochar et al., 2000, Cantarino et al., 2013, Miki et al., 1994). They are 
associated with breast cancer development, but not linked to HCC so far. Both genes are 
upregulated in stably H19 overexpressing hepatoma cells, with H2AFY2 reaching 
statistical significance. These findings indicate that H19 acts, in part, as an inducer of 
tumor suppressors. 
Another interesting predicted H19 target is SLC15A1. It belongs to the solute carrier (SLC) 
membrane transporters, which are often involved in drug resistance (Hediger et al., 2004). 
The upregulation of SLC15A1 expression under stable H19 overexpression – which 
caused chemosensitization in hepatoma cells – suggests a role of SLC15A1 in 
chemoresistance of HCC. 
In summary, the experimentally verified bioinformatic predictions endorse the molecular 
sponge function as an important biological action of H19 modulating the expression of 
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different gene classes including epigenetic regulators, tumor suppressors, and drug 
transporters.  
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H19 proteins  
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Introduction 
 
Although H19 was described as a non-coding RNA because of the absence of a protein 
in mice (Brannan et al., 1990), Onyango and Feinberg identified in 2011 the H19 opposite 
tumor suppressor (HOTS) protein (17 kDa) encoded by the H19 antisense transcript. 
Furthermore, Gascoigne et al. composed in 2012 a suite of programs for the identification 
of novel proteins resulting, among others, in the detection of H19 sense protein (26 kDa). 
The HOTS protein is maternally expressed in primates, while no open reading frame 
(ORF) for this protein was found in mice (Onyango & Feinberg, 2011). Onyango and 
Feinberg reported a tumor growth inhibitiory function of HOTS, which was not confirmed 
by others so far. 
The expression of H19 sense protein was identified only in fetal liver, a myelogenous 
leukemia cell line (K562), and in testes (Gascoigne et al., 2012), while functional analyses 
of this protein have not been performed to date. 
In this chapter, the existence of HOTS and H19 sense protein is reported in three different 
hepatoma cell lines. Investigations of their expression in long-term doxorubicin- and 
sorafenib-treated cells, as well as in chemosensitized hepatoma cells were undertaken to 
clarify the function of these proteins during chemoresistance.  
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Results 
 
Investigations of HOTS and H19 sense proteins in HepG2, Plc/Prf/5, and Huh7 cells 
showed detectable baseline expression (Figure 1A). While the basal H19 mRNA 
expression showed highly significant differences between the hepatoma cell lines (4,539-
fold higher H19 mRNA expression in Plc/Prf/5 than in HepG2) (Figure 1B), the H19 
proteins were rather equally expressed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: H19 protein and H19 mRNA baseline expression. (A) Basal levels of H19 sense and H19 
antisense protein in HepG2, Plc/Prf/5, and Huh7 cells. A representative Western blot is shown (n=3, 
duplicates). (B) Baseline H19 mRNA expression determined by qPCR in HepG2, Plc/Prf/5, and Huh7 cells 
(n=5, duplicates). The p values were calculated by Mann-Whitney U test.  
Chapter 5 
72 
 
H19 proteins in stably H19 overexpressing cells 
 
In order to clarify whether H19 mRNA or the proteins derived from the H19 locus were 
responsible for the chemosensitizing action in the stably H19 overexpressing cell lines, 
potential changes in protein expression were determined. The expression of H19 sense 
protein was not altered in any of the stably H19 overexpressing cells (Figure 2A). The 
HOTS (H19 antisense) protein level was only increased in stably H19 overexpressing 
HepG2 cells and not elevated in the stably H19 overexpressing Plc/Prf/5 and Huh7 cells 
(Figure 2B). Hence, due to minor or no alterations of the protein levels, it seems rather 
unlikely that the increased chemosensitivity of stably H19 overexpressing cells was 
facilitated by H19 sense or HOTS protein. 
 
 
 
Figure 2: Effect of stable H19 overexpression on (A) H19 sense and (B) H19 antisense protein levels. 
Representative Western blots are shown (left panels). H19 sense and H19 antisense protein levels in H19 
overexpressing (H19) HepG2, Plc/Prf/5, and Huh7 cells compared to respective control cells (co) are 
normalized to tubulin (right panels, n=2, duplicates).  
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H19 proteins in chemoresistance 
 
To elucidate the role of H19 proteins in chemoresistance, their levels were examined in 
doxorubicin and sorafenib resistant cells. All doxorubicin resistant cell lines exhibited a 
downregulation of the H19 sense protein compared to the respective chemosensitive cell 
lines. The H19 antisense protein was significantly downregulated in HepG2 and Plc/Prf/5 
cells, while the data did not reach statistical significance in Huh7 cells (Figure 3). 
 
 
 
Figure 3: Influence of doxorubicin resistance on H19 sense and H19 antisense protein expression. 
Representative Western blots are shown (left panels). H19 sense (upper panels) and H19 antisense (lower 
panels) protein levels in doxorubicin resistant (resistant, Dox-R) HepG2, Plc/Prf/5, and Huh7 cells compared 
to respective control cells (co) were normalized to tubulin (right panels, n=3, triplicates). 
 
Regarding sorafenib resistance, neither alteration of H19 sense nor antisense protein 
expression could be detected (Figure 4). These findings suggest a potential role of H19 
proteins in doxorubicin resistance but not in sorafenib resistance.  
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Figure 4: Influence of sorafenib resistance on H19 sense and H19 antisense protein expression. 
Representative Western blots are shown (left panels). H19 sense (upper panels) and H19 antisense (lower 
panels) protein levels in sorafenib resistant (resistant, Sora-R) HepG2, Plc/Prf/5, and Huh7 cells compared 
to respective control cells (co) were normalized to tubulin (right panels, n=3, triplicates). 
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Discussion 
 
The imprinted H19 locus contains one of the first identified long non-coding RNA genes 
(Brannan et al., 1990). However, our results confirmed the presence of the H19 sense 
and HOTS proteins in the human system as reported by Gascoigne et al. and Onyango 
and Feinberg (Gascoigne et al., 2012, Onyango & Feinberg, 2011): to our knowledge the 
expression of H19 proteins in the hepatoma cell lines HepG2, Plc/Prf/5, and Huh7 was 
shown for the first time.  
A correlation between H19 mRNA and H19 sense protein expression could not be 
identified: while H19 mRNA was overexpressed up to 65-fold in the stably transfected 
cells and downregulated in sorafenib-resistant cells, no significant alteration in the 
expression of the H19 sense protein was detectable. Further, the hepatoma cell lines 
showed highly different baseline levels of H19 mRNA, but the H19 sense protein was 
almost equally expressed. These findings gave a hint towards a potential post-
transcriptional inhibition of translation into H19 sense protein. 
The HOTS protein was significantly downregulated during doxorubicin resistance in two 
of three cell lines. This finding is in line with the tumor-suppressive function of HOTS 
described by Onyango and Feinberg (Onyango & Feinberg, 2011). 
Interestingly, HepG2 cells overexpressing H19 mRNA revealed a significantly upregulated 
HOTS expression, whereas doxorubicin resistant HepG2 cells, in which the H19 mRNA 
expression was significantly downregulated, showed lower HOTS levels. This positive 
correlation between the expression of a mRNA and a protein derived from the antisense 
transcript of this mRNA has not been described so far and has to be further investigated. 
The expression of H19 proteins was not altered in stably H19 overexpressing cells, which 
showed increased sensitivity towards doxorubicin and sorafenib treatment (as shown in 
chapter 3). Thus, the H19 proteins are unlikely to be responsible for the chemosensitizing 
actions of H19 overexpression. These findings underline our hypothesis that H19 mRNA 
itself - and not the proteins derived from the H19 locus - caused the sensitization of 
hepatoma cells. 
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1. Materials 
 
Materials are listed in Table 1. All other chemicals were obtained from Roth (Karlsruhe, 
Germany) or Sigma-Aldrich (Taufkirchen, Germany). 
 
Table 1: Materials and respective order information. 
Material Company City Country 
10x buffer C  Solis BioDyne  Tartu Estonia 
10x Hot Star Taq-buffer Qiagen Hilden Germany 
10x Taq-buffer GenScript Piscataway USA 
7x Complete protease inhibitor  Roche Mannheim Germany 
5x HOT FIREPol Evagreen qPCR 
Mix Plus 
Solis BioDyne  Tartu Estonia 
AluI Fermentas St. Leon-Rot Germany 
Ambion linear acrylamide Invitrogen Darmstadt Germany 
Anti-human RAC1, mouse IgG 
clone 23A8 
Merck Millipore Darmstadt Germany 
Biotin- and digoxin labeled probes  Exiqon  Vedbaek Denmark 
ddCTP Larova Jena Germany 
ddTTP Larova Jena Germany 
DNA free Kit Invitrogen Darmstadt Germany 
dNTPs mix GenScript Piscataway USA 
Exonuclease I/SAP shrimp alkaline 
phosphatase  
USB Corporation  Cleveland USA 
EZ DNA Methylation-Gold Kit  Zymo Research Freiburg Germany 
Flow cytometry buffer (FCB) BD Biosciences Heidelberg Germany 
Geneticin Invitrogen Darmstadt Germany 
Glass membrane slides Leica Microsystems CMS Wetzlar Germany 
Glutathione sepharose beads GE Healthcare Life 
Sciences  
Freiburg Germany 
High-Capacity cDNA Reverse 
Transcription Kit 
Invitrogen Darmstadt Germany 
HiSpec Buffer Qiagen Hilden Germany 
Hot Star Taq-polymerase Qiagen Hilden Germany 
Immobilon FL-PVDF membrane  Rockland 
Immunochemicals Inc.  
Limerick USA 
INTERFERin Polyplus-Transfection Illkirch France 
IRDye 800CW conjugated goat, 
anti-mouse IgG  
Li-COR Biosciences  Bad Homburg Germany 
IRDye 800CW conjugated goat, 
anti-rabbit IgG  
Li-COR Biosciences  Bad Homburg Germany 
jetPEI Hepatocyte reagent VWR International GmbH  Darmstadt Germany 
LNA gapmers Exiqon  Vedbaek Denmark 
MgCl2 solution Qiagen Hilden Germany 
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miCURY LNA microRNA ISH 
Optimization Kit (FFPE)  
Exiqon  Vedbaek Denmark 
Nuclear Fast Red Counterstain  Vector Laboratories Burlingame USA 
PKD buffer  Qiagen Hilden Germany 
Primers Eurofins Genomics Ebersberg Germany 
Proteinase K Roche Mannheim Germany 
QIAamp DNA FFPE Tissue Kit  Qiagen Hilden Germany 
QIAzol lysis reagent Qiagen Hilden Germany 
RAC1 inhibitor NSC23766 R&D Systems  Wiesbaden Germany 
Recombinant DLK1  R&D Systems  Wiesbaden Germany 
RNaseOUT Invitrogen Darmstadt Germany 
RNeasy FFPE Kit  Qiagen Hilden Germany 
Rockland Blocking Buffer Rockland Immuno-
chemicals Inc.  
Limerick USA 
Sorafenib Biomol GmbH Hamburg Germany 
Taq-polymerase GenScript Piscataway USA 
TermiPol Solis BioDyne  Tartu Estonia 
Tsp509I  New England Biolabs  Ipswich USA 
 
 
2. Mice 
 
2.1 Animal welfare 
 
All animal procedures were performed in accordance with the local animal welfare 
committee (approval number 36/2013). Mice were kept under controlled conditions 
regarding temperature, humidity, 12 h day/night rhythm, and food access. 
 
2.2 Generation of p62 transgenic H19 knockout mice 
 
Female C57BL/6J mice carrying a liver enriched activator protein under control of a 
tetracycline transactivator (tTA) (Tybl et al., 2011) (LT2 positive mice) were crossed with 
male 129sv H19 knockout (H19 ko) mice, in which a 3 kb region of the H19 gene was 
replaced by a neomycin resistance gene (neo) cassette (Gabory et al., 2010, Ripoche et 
al., 1997). The littermates carried the H19 ko on the maternal allele, whereas the paternal 
allele remained wild-type (wt). Female LT2 positive H19 ko mice were bred with male 
DBA2J p62 transgenic mice, in which p62 expression was repressed by the TRE-CMVmin 
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promoter. In the obtained p62 positive LT2 positive mice, the tetracycline transactivator 
derepressed the TRE-CMVmin promoter and thereby allowed human p62 expression in 
mouse livers (p62 tg). The following four genotype groups were generated: H19 wt/p62 
wt, H19 ko/p62 wt, H19 wt/p62 tg, and H19 ko/p62 tg mice. 
 
2.3 Genotyping  
 
For genotyping of mice, an ear biopsy was taken and digested with proteinase K (0.2 
mg/ml) in Taq-buffer at 55°C. After total lysis of the tissue, PCRs were performed using 
the following conditions and primer sequences (Table 2): 
 
H19 wild-type 
Reaction mixture      PCR program 
Evagreen  4 µl    94°C  5 min 
Primer (10 µM) 0.4 µl    94°C  45 sec 
H2O   11.2 µl   58°C  45 sec 30x 
Template DNA  4 µl    72°C  1 min 
       72°C  7 min 
 
Neo 
Reaction mixture      PCR program 
10xTaq-buffer 5 µl    95°C  5 min 
MgCl2 (50 mM) 1.5 µl    66°C  1 min 
dNTPs (10 mM) 1 µl    72°C  1 min 
Primer (10 µM) 1 µl    95°C  20 sec 
Taq-Polymerase 0.25 µl   66°C  30 sec 35x 
H2O   39.25 µl   72°C  1 min 
Template DNA  2 µl    72°C  10 min 
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p62/tTA 
Reaction mixture      PCR program 
10xTaq-buffer 2 µl    94°C  5 min 
dNTPs (10 mM) 0.25 µl   94°C  30 sec 
Primer (10 µM) 1 µl    57°C  30 sec 35x 
Taq-Polymerase  1 µl    72°C  30 sec 
H2O   11.75 µl   72°C  5 min 
Template DNA  1 µl 
 
Table 2: Primer information for genotyping PCRs. 
Target 
 
Forward primer 
sequence 5’ → 3’ 
Reverse primer 
sequence 5’ → 3’ 
Product 
size 
Neo GTGTTCCGGCTGTCAGCGCA GTCCTGATAGCGGTCCGCCA 500 bp 
H19 wt CCATCTTCATGGCCAACTCT AATGGGGAAACAGAGTCACG 150 bp 
tTA GTGCAGAGCCAGCCTTCTTA CCTCGATGGTAGACCCGTAA 150 bp 
p62 CATCAAACAGCTGGCGAGAT GTGCCCGATAATTCTGACGA 450 bp 
 
 
2.4 Treatment 
 
Short-term DEN experiment 
 
For the short-term experiment nine week old wild-type male C57BL/6J mice were 
intraperitoneally injected with either 100 mg/kg body weight DEN or NaCl as sham-control 
(each, n=5). Mice were sacrified 48 h after the injection (Kessler et al., 2015, Naugler et 
al., 2007, Park et al., 2010). 
 
H19 ko/p62 tg mice (long-term DEN experiment) 
 
Mice were intraperitoneally injected with 5 mg/kg body weight DEN diluted in saline at the 
age of two weeks and sacrificed 24 weeks after injection. Untreated mice served as control 
(Figure 1). Analyses were performed with the whole number of experimental mice unless 
stated otherwise. 
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Figure 1: Genotype and treatment groups of experimental mice. 
 
 
2.5 Preparation of liver tissue 
 
Livers were excised and weighed. Each lobe of the liver was divided into two pieces. One 
piece was flash-frozen in liquid nitrogen and stored at -80°C, the other one was fixed in 
PBS-buffered formalin and embedded in paraffin for histological analyses. One piece of 
the left lateral lobe was used for RNA extraction.  
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2.6 Histological and immunohistological analyses of mouse livers 
 
5 µm and 0.5 µm slices from paraffin-embedded mouse livers were cut with a microtome 
(Slee, Mainz, Germany). 5 µm slices were stained either with hematoxylin-eosin (H&E) for 
the detection of tumors, inflammation, and apoptosis, or with Sirius Red to analyze 
fibrosis. 0.5 µm slices were used for the immunohistological staining of the HCC marker 
glutamine synthetase (GS), tumor specific surface antigen Golgi membrane protein 73 
(Gp73), and proliferation marker Ki67. Antibodies and immunostaining conditions are 
listed in Table 3. The scoring was performed in collaboration with Prof. Dr. Dr. Johannes 
Haybäck from the Institute of Pathology (Medical University of Graz) and the Department 
of Pathology (Medical Faculty, Otto-von-Guericke University Magdeburg) blinded to 
experimental conditions. 
 
Table 3: Antibodies and conditions for immunostaining. 
Antibody Product 
no. 
Company Demasking Dilution Detection 
anti-Gp73 sc-48011 Santa Cruz, 
Heidelberg, 
Germany 
citrate buffer pH 6.0, 
microwave 
1:200 rabbit-anti-goat 
(#A50-204A, Bethyl), 
Dako Envision, DAB 
anti-GS AB1783 Millipore, 
Temecula, CA, 
USA 
CC1 mild (Ventana), 30 
min 
1:5,000 Ultra View (Vantana), 
DAB 
anti-Ki67 PA0230 Novocastra, 
Newcastle, UK 
citrate buffer pH 6.0, 
microwave 
1:1,000 Dako Endvision, AEC 
 
 
3. Cell culture 
 
3.1 Cell lines 
 
HepG2, Huh7, and Plc/Prf/5 cells were cultured in RPMI-1640 medium with 10% fetal calf 
serum, 1% penicillin/streptomycin, and 1% glutamine at 37°C and 5% CO2. All cell lines 
were authenticated by the DSMZ (Braunschweig, Germany). 
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3.2 H19 knockdown 
 
H19 knockdown was performed in 96-well plates with 21,000 HepG2, 17,500 Plc/Prf/5, or 
14,000 Huh7 cells in 140 µl medium per well and antisense LNA gapmer for H19 (5’-
GACTTAGTGCAAATTA-3’) or negative control A (5’-AACACGTCTATACGC-3’) (gapmer 
concentration per well: HepG2: 0.04 µM, Plc/Prf/5: 0.02 µM, and Huh7: 0.03 µM) using 
INTERFERin transfection reagent (35 µl mastermix per well) as recommended by the 
manufacturer. The negative control shows no homology to any known microRNA, lncRNA, 
or mRNA. H19 knockdown was confirmed by qPCR. 
 
3.3 Stable H19 overexpression 
 
Stable H19 overexpression in hepatoma cells was established by transfection with a 
vector (pcDNA3.1(+)_A009) containing the synthetic H19-sequence or the empty vector 
as control (Suppl. Figure S1) (Ref. No.: 1381790, Life Technologies, California, USA). 
Vector synthesis and sequencing were performed by Life Technologies. 
50.000 hepatoma cells in 1 ml medium per well were seeded into 24-well plates and 
transfected 24 h after seeding using jetPEI Hepatocyte reagent as recommended by the 
manufacturer. Resistance to geneticin was conferred by the neomycin resistance gene 
(Neo (R)). The geneticin concentrations used for selection were determined by MTT assay 
(HepG2 and Plc/Prf/5 cells: 500 µg/ml, Huh7 cells: 125 µg/ml). 
Transient H19 overexpression in chemoresistant cells was performed accordingly, but 
cells were treated with doxorubicin or sorafenib (HepG2-Dox-R: 2 µg/ml; Huh7-Sora-R: 
2.5 µM) simultaneously with the plasmid transfection for 48 h or 72 h. H19 overexpression 
was confirmed by qPCR. 
 
3.4 Establishment of chemoresistant cells 
 
Doxorubicin resistant (HepG2-Dox-R, Huh7-Dox-R, and Plc/Prf/5-Dox-R) and sorafenib 
resistant (HepG2-Sora-R, Huh7-Sora-R, and Plc/Prf/5-Sora-R) cells were established by 
treatment with increasing concentrations of the cytostatic drugs over several months. 
Chemoresistance was confirmed by MTT assay and MDR1 expression. 
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In order to maintain the resistance, cells confluent grown in a 175 cm2 cell culture flask 
were treated biweekly with doxorubicin (HepG2-Dox-R: 5 µg/ml, Huh7-Dox-R: 1 µg/ml, 
and Plc/Prf/5-Dox-R: 10 µg/ml) or sorafenib (HepG2-Sora-R, Huh7-Sora-R, and Plc/Prf/5-
Sora-R: 5 µM) in 10 ml medium. 24 h after the treatment, the medium was removed and 
the living cells were transferred into a 75 cm2 cell culture flask. The medium was 
exchanged everyday until no dead cells were left. 
For mRNA and protein analysis, 400,000 cells per well were seeded into 6-well plates and 
allowed to attach overnight. They were treated with doxorubicin (HepG2-Dox-R: 2 µg/ml, 
Huh7-Dox-R: 0.5 µg/ml, and Plc/Prf/5-Dox-R: 5 µg/ml) or sorafenib (HepG2-Sora-R, 
Huh7-Sora-R, and Plc/Prf/5-Sora-R: 2.5 µM) in 1 ml medium for 72 h before washing with 
1 ml PBS per well, and lysis with QIAzol or SB lysis buffer with freshly added 7x Complete 
protease inhibitor. 
 
Doxorubicin and sorafenib were dissolved in dimethyl sulfoxide (DMSO) and stock 
solutions (doxorubicin: 50 mg/ml, sorafenib: 40 mg/ml) were prepared. MTT tests were 
performed to detect the influence of DMSO on cell viability (Suppl. Figure S4-6). 
 
3.5 Cytotoxicity assay (MTT assay) 
 
Hepatoma cells (10,000 HepG2, 5,000 Plc/Prf/5, or 5,000 Huh7) were seeded into 96-well 
plates and treated with different concentrations of doxorubicin, sorafenib, or the respective 
solvent control the next day. 24 h after treatment, medium was removed and 100 µl of 0.5 
mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) 
diluted in medium was added. After 2 h incubation, the medium was removed, formazan 
crystals were dissolved in 80 µl DMSO, and the absorbance was measured at 550 nm 
with 630 nm as reference wavelength in a microplate reader (Tecan Sunrise, Tecan Group 
Ltd., Männedorf, Switzerland). 
For MTT assay after the 5-azacytidine treatment, cells were treated over four days with 2 
µM of the methyltransferase inhibitor 5-azacytidine, which was freshly added each day. 
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3.6 Clonogenicity assay 
 
Hepatoma cells were seeded into 6-well plates (Plc/Prf/5 and Huh7: 500 cells per well; 
HepG2: 5,000 cells per well), allowed to attach overnight, and treated with the indicated 
concentrations of sorafenib, doxorubicin, or the respective solvent control in 1 ml medium 
for 24 h. Following the treatment, cells were washed with PBS and allowed to form 
colonies in 2 ml complete growth medium. After 10 to 15 days, the colonies were fixed in 
methanol, stained with crystal violet, and counted. For the sorafenib experiments colonies 
were counted with a clono counter software as previously described (Niyazi et al., 2007, 
Tripathi et al., 2015) and for the doxorubicin experiments colonies were counted manually. 
 
 
4. RNA isolation and quantitative real-time RT-PCR (qPCR) 
 
Total RNA was extracted with QIAzol lysis reagent according to the manufacturer`s 
instructions. Potential contamination with DNA was removed by DNase digestion using 
the DNA free Kit. Reverse transcription of 0.5 µg RNA was performed with the High-
Capacity cDNA Reverse Transcription Kit using random primers. For microRNA analysis, 
the procedure was performed accordingly with minor modifications: (I) the RNA after 
isopropanol precipitation was not washed with ethanol and (II) reverse transcription with 
2 µg RNA was performed using the miScript II RT Kit and HiSpec Buffer as recommended 
by the manufacturer. Samples along with plasmid standard dilution series from 80 to 
0.00008 attomol were run in triplicates using 5x HOT FIREPol Evagreen qPCR Mix Plus 
in a CFX96 cycler (Bio-Rad, Munich, Germany) with specific primers (Table 4). The 
reaction conditions for the detection of mRNAs were 95°C for 15 min followed by 40 cycles 
of 30 sec at 94°C, 30 sec at primer-specific annealing temperature (AT listed in Table 4), 
and 30 sec at 72°C. A melting curve from 55°C to 95°C was recorded to detect potential 
unintended products. For the detection of microRNAs the reaction conditions were 95°C 
for 15 min, followed by 40 cycles of 15 sec at 94°C, 30 sec at primer-specific annealing 
temperature (AT listed in Table 4), and 30 sec at 70°C. The human gene expression 
samples were normalized to actin beta (ACTB), murine samples to casein kinase 2 alpha 
2 (Csnk2a2), and microRNAs were normalized to RNU6B. 
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For the detection of H19 sponge targets, the mRNA value stability of three housekeeping 
genes (actin beta (ACTB), 18S ribosomal 5 (RNA18S5), and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)) was compared with the geNorm test (Vandesompele et al., 
2002). Since all M-values were less than 1.5 (ACTB M=0.605, RNA18S5 M=0.683, and 
GAPDH M=0.552), the gene expression was normalized to their geometric mean 
(Vandesompele et al., 2002). 
 
Q-PCR experiments shown in chapter 2 were performed by Beate Czepukojc from the 
Department of Pharmacy (Pharmaceutical Biology, Saarland University). 
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Table 4: Target gene-specific primer information. 
mRNA Forward primer 
sequence  
5’ → 3’ 
Reverse primer 
sequence  
5’ → 3’ 
Gene bank 
accession no. 
AT 
[°C] 
Product 
size 
[bp] 
Primer 
conc. 
[µM] 
hu ABCB1/ 
hu MDR1 
GCTATAATGC
GACAGGAGAT
AGGCT 
CATTCCAATTT
TGTCACCAAT
AACTT 
NM_001348946.1; 
NM_001348945.1; 
NM_001348944.1 
56 116 0.2 
hu ACTB TGCGTGACAT
TAAGGAGAAG 
GTCAGGCAGC
TCGTAGCTCT 
NM_001101.3 60 107 0.2 
hu AFP TTCTTTGGGC
TGCTCGCTAT 
TGCTGCCTTT
GTTTGGAAGC 
NM_001134.2 60 86 0.2 
hu BRCA1 GCTCTTCGCG
TTGAAGAAGT
A 
ATCAACTCCA
GACAGATGGG
A 
NM_007294.3; 
NM_007299.3; 
NM_007298.3; 
NM_007300.3 
60 80 0.2 
hu CCNB1 
IP 
ATGGTGAATG
GACACCAACT
CT 
CATTCTTAGC
CAGGTGCTGC 
 
NM_031966.3  
 
60 87 0.25 
hu CTSV GAAGGCCGCC
TGGAAACTT 
AGGCACCCTC
AGCAAACAAG 
NM_001333.3 62 94 0.15 
hu DNMT3B AGCAGCCCTG
GAGACTCATT 
CACGACGCAC
CTTCGACTTAT 
NM_006892.3 60 139 0.2 
hu E2F8 TGAACTGGCC
ACCCGAACA 
CCCAAAGCTC
CAAGTATGCA
GT 
NM_024680.3 60 128 0.2 
hu ELAVL1 GGTGACATCG
GGAGAACGAA 
CCAAGCTGTG
TCCTGCTACT 
NM_001419.2 60 142 0.2 
hu GAPDH GGGAAGGTGA
AGGTCGGAGT 
TCCACTTTACC
AGAGTTAAAA
GCAG 
NM_002046.5; 
NM_001289745.1; 
NM_001289746.1 
60 82 0.2 
hu GAPDH 
IP 
TTCGACAGTC
AGCCGCATCT 
GCCCAATACG
ACCAAATCCG
TT 
NM_002046.5 
 
63 105 0.2 
hu H19 TTCAAAGCCT
CCACGACTCT 
CTGAGACTCA
AGGCCGTCTC 
NR_131224.1; 
NR_131223.1; 
NR_002196.2; 
NM_001293171.2 
60 100 0.2 
hu H19 IP GCTCCCAGAA
CCCACAACAT 
CCTTCCAGAG
CCGATTCCTG 
NR_131224.1; 
NR_131223.1; 
NR_002196.2; 
NM_001293171.2 
61 149 0.2 
hu H2AFY2 CGGATAGCCC
CGAGACACAT 
TCCACTGGCG
ATGGTCACTC 
NM_018649.2 60 87 0.2 
hu IGF2 GGACTTGAGT
CCCTGAACCA 
TGAAAATTCC
CGTGAGAAGG 
NM_000612.5; 
NM_001007139.5;
NM_001127598.2;
NM_001291861.2;
NM_001291862.2 
56 100 0.25 
hu IKBKAP TCCAGGGAAT
CCTCAGTGCT
T 
AGCCTTCTGC
CACCAAAGAA
A 
NM_001330749.1; 
NM_003640.4 
60 134 0.2 
hu KDELC1 ACCGTCATAC
TTCTCTTGCTC
C 
CCAAAGGCCA
GTCTCCCAAA
T 
NM_001318732.1 60 144 0.2 
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hu MYBL2 AGATTCAGAT
GTGCCGGAGC 
TGTCCAAACT
GCCTCACCAG 
NM_002466.3 60 99 0.2 
hu NINL TCATCCCTCG
TGTCCCTGTG 
TCTGCAAGAT
CTCCCTGCCA
T 
NM_001318226.1; 
NM_025176.5 
60 136 0.2 
hu RNA18S5 AGGTCTGTGA
TGCCCTTAGA 
GAATGGGGTT
CAACGGGTTA 
NR_003286.2 61 109 0.2 
hu SLC15A1 GCCATCGTGC
AGGTGGAAAT 
TGGGCCAAGT
GTCACCATCT 
NM_005073.3 60 135 0.2 
hu SMYD3 GAGCCGCTGA
AGGTGGAAAA
G 
TGTACGCCAA
GGGATCCGAG 
NM_001167740.1 60 112 0.2 
hu SOAT2 CCGCAAGTCC
CTGCTTGAT 
GCCAGCGATG
AACATGTGGT
A 
NM_003578.3 60 73 0.2 
hu WASF1 GCAGTGTTCT
CTTCGTCCC 
CCCCCTTTCC
TGAGGTTCT 
NM_001024936.1; 
NM_001024935.1; 
NM_001024934.1; 
NM_003931.2 
60 70 0.2 
mu H19 CAGAGGTGGA
TGTGCCTGCC 
CGGACCATGT
CATGTCTTTCT
GTC 
NR_001592.1 60 80 0.25 
mu Igf2 GGAAGTCGAT
GTTGGTGCTT
CTC 
CGAACAGACA
AACTGAAGCG
TGT 
NM_010514.3 60 121 0.2 
mu Csnk2a2 GTAAAGGACC
CTGTGTCAAA
GA 
GTCAGGATCT
GGTAGAGTTG
CT 
NM_009974.3 60 85 0.4 
miRNA Forward primer 
sequence  
5’ → 3’ 
Reverse primer  
sequence  
5’ → 3’ 
Accession no. AT 
[°C] 
 Primer 
conc. 
[µM] 
hsa-miR-675 TGGTGCGGAA
AGGGCCCACA
GT 
GAATCGAGCA
CCAGTTACGC
AT 
MIMAT0004284 64  0.2 
RNU6B ACGCAAATTC
GTGAAGCGTT 
GAATCGAGCA
CCAGTTACG 
e.g. NR_125730.1 55  0.5 
 
AT: annealing temperature 
 
 
5. DNA methylation analysis 
 
5.1 DNA extraction and bisulfite conversion 
 
Genomic DNA from HepG2, Plc/Prf/5, and Huh7 cells was extracted with the GenElute 
Mammalian Genomic DNA Miniprep Kit and bisulfite treatment of 500 ng genomic DNA 
was performed with the EZ DNA Methylation-Gold Kit according to the manufacturer’s 
instructions. 
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5.2 Single nucleotide primer extension (SNuPE) 
 
Amplicons were generated using region-specific primers for the H19 promoter (forward 
(5’-3’): GGGTTTGGGAGAGTTTGTGAGGT; reverse (5’-3’): AACACAAAAAACCCC 
TTCCTACCA) and the following PCR reaction conditions: 
 
Reaction mixture      PCR program 
10x buffer   3 µl   95°C  15 min 
dNTPs (10 mM)  2.4 µl    95°C  1 min 
Primer (10 µM)  0.5 µl   57.6°C 1 min  42x 
Hot Star Taq (5 U/µl) 0.3 µl   72°C  1 min 
H2O    21.3 µl  72°C  5 min    
Bisulfite DNA   2 µl     
 
A restriction digestion using Tsp509I (cutting site shown in Figure 2) was performed in 
order to enhance the SNuPE signal. Remaining primers were degraded with Exonuclease 
I/SAP shrimp alkaline phosphatase (1 U/ 9 U).  
 
                          GGGTTTGGGAGAGTTTGTGAGGTCGTTTATCGTTTGTTAG 150 
 151  TAGAGTGCGTTCGCGAGTCGTAAGTATAGTTCGGTAATATGCGGTTTTTAGATAGGAAAG 210 
 211  TGGTCGCGAATGGGATCGGGGTGTTTAGCGGTTGTGGGGATTTTGTTTTGCGGAAATCGC 270 
 271  GGTGATTAGTATAAGTTCGGTTAATTGGATGGGAATCGGTTTGGGGGGTTGGTATCGCGT 330 
 331  TTATTAGGGGGTTTGCGGTATTTTTTTTTGTTTTTTAGTATTTTATTTTTATTTTTTAGG 390 
 391  AACGTGAGGTTTGAGTCGTGATGGTGGTAGGAAGGGGTTTTTTGTGT 
 
Figure 2: Bisulfite DNA sequence of the analyzed H19 promoter region (blue: PCR primers, red: SNuPE 
primers, gray: CpGs, and purple: Tsp509I cutting site 5’-   AATT – 3’)). 
 
The single nucleotide primer extension for two CpG sites of the H19 promoter (CpG 3 
primer (5’-3’): TGTTAGTAGAGTG and CpG 17 primer (5’-3’): GTGATTAGTATAAGTT) 
was performed under the following conditions: 
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Reaction mixture      PCR program 
10x buffer C   2 µl   96°C  2 min 
ddCTP (1 mM)  1 µl    96°C  30 sec 
ddTTP (1 mM)  1 µl   50°C  30 sec 50x 
Primer (30 µM)  2.4 µl   60°C  1 min 
TermiPol (5 U/µl)  1 µl       
MgCl2 (25 mM)  1.6 µl 
H2O    2.6 µl 
ExoSAP product   6 µl  
 
SNuPE products were seperated using ion pair reversed phase high performance liquid 
chromatography (IP/RP-HPLC) with an HPLC WAVE 3000 (Transgenomic), a DNASep-
Column at 50°C, and a flow rate of 0.9 ml/min.     
 
5.3 Local deep bisulfite sequencing (Bi-PROF) 
 
For the analysis with next generation sequencing, the recommended adaptors were 
added to the primer sequences for the amplicon generation (forward (5’-3’): TCTTTC 
CCTACACGACGCTCTTCCGATCTGGGTTTGGGAGAGTTTGTGAGGT and reverse (5’-
3’): GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTAACACAAAAAACCCCTTCCT 
ACCA, annealing temperature 60°C). Purified PCR products were pooled in an equimolar 
ratio and sequenced (Gries et al., 2013) on a MiSeq instrument with the sequencing-by-
synthesis technology (2 x 300 bp paired-end) aiming at 10,000 reads per amplicon 
according to the manufacturer’s protocol. 
 
DNA methylation analysis was performed in cooperation with Dr. Sascha Tierling and Prof. 
Dr. Jörn Walter from the Department of Genetics and Epigenetics (Saarland University). 
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6. Western blot analysis 
 
Total proteins from HepG2, Plc/Prf/5, and Huh7 cells were extracted using the SB lysis 
buffer (50 mM Tris pH 6.8, 1% [w/v] SDS, 10% [w/v] glycerol, 0.004% [w/v] bromophenol 
blue, and 5% [w/v] β–mercaptoethanol in distilled water) with freshly added 7x Complete 
protease inhibitor. Samples were mixed with loading buffer, denatured for 10 min at 95°C, 
and loaded onto a 12% polyacrylamide gel. Proteins were separated with SDS-PAGE and 
transferred to an Immobilon FL-PVDF membrane. After blocking for 1 h with Rockland 
Blocking Buffer (RBB), the membrane was incubated with H19 antisera (1:5,000 dilution 
for H19 sense protein and 1:2,000 dilution for H19 antisense protein in RBB) obtained 
from John S. Mattick (Institute for Molecular Bioscience, University of Queensland, St 
Lucia, Brisbane, Queensland 4072, Australia) for 1 h. Subsequently, the membrane was 
washed and incubated with the labeled secondary antibody anti-rabbit 800 (1:5,000 
dilution in RBB) for 1 h. Signal intensities were determined using the Odyssey infrared 
image system (LI-COR, Biosciences, Bad Homburg, Germany).  
 
Experiments were carried out in part by Dr. Stephan Laggai from the Department of 
Pharmacy (Pharmaceutical Biology, Saarland University). 
 
 
7. RAC1 pull-down assay 
 
For the detection of activated RAC1, the affinity to the p21 binding domain of its target 
p21-activated kinase 1 was utilized. A fusion protein consisting of glutathione S-
transferase and the p21 binding domain (GST-PBD) was expressed in Escherichia coli, 
purified, and bound to glutathione sepharose beads (Diesel et al., 2013, Fürst et al., 2005). 
For RAC1 pull-down assays, HepG2 seeded in a density of 8 × 105 cells per well in 6-well 
plates were treated with 1 µg/ml DLK1 for 2 or 5 min. After a washing step with ice-cold 
PBS, samples were lysed with PBD-buffer (Tris pH 8.0 25 mM, DTT 1 mM, MgCl2 20 mM, 
NaCl 100 mM, EDTA 0.5 mM, Triton X-100 1%, Aproptinin 0.1%, Leupeptin 0.1%, and 
PMSF 0.1%) and the positive control (untreated HepG2 cells) with GTPγS-PBD-buffer 
(Tris pH 8.0 25 mM, DTT 1 mM, MgCl2 5 mM, NaCl 100 mM, EDTA 1 mM, Triton X-100 
Materials and Methods 
92 
 
1%, Aproptinin 0.1%, Leupeptin 0.1%, and PMSF 0.1%). The cell lysate was incubated 
for 15 min at 4°C under vigorous shaking to complete lysis. The positive control was 
incubated for 10 min with GTPγS (10 mM) to enrich the activated form of RAC1 (RAC-
GDP  RAC-GTP). This reaction was stopped by adding MgCl2 (1 M). The cell lysates 
were centrifuged and the supernatants were incubated with 30 µl GST-PBD-beads for 2 
h at 4°C under vigorous shaking. After centrifugation and washing with PBD-buffer or 
GTPγS-PBD-buffer (for the positive control), the pellet containing a complex of GST-PBD-
bound activated RAC1 was frozen at -80°C.  
Western blot analysis was performed as described in chapter 6 using the primary antibody 
for human RAC1 (1:500 dilution in RBB) overnight at 4°C, followed by incubation with 
IRDye-conjugated secondary antibody for 1.5 h.  
 
 
8. ROS assay 
 
HepG2 cells seeded in a density of 50,000 cells per well in a 96-well plate were loaded 
with 20 μmol/l dichlorodihydrofluorescein diacetate (DCDHF) in PBS for 60 min and 
treated with 0.5 or 1 µg/ml DLK1 for up to 30 min. For the inhibition of RAC1, cells were 
pretreated with NSC23766 together with DCDHF. 300 µM H2O2 served as positive control 
for the ROS induction. Fluorescence (excitation, 485 nm; emission, 535 nm) was 
measured in a SpectraMax M5e (Moleculardevices, Biberach, Germany).  
 
 
9. Bioinformatic analyses 
 
9.1 TCGA data 
 
RNAseq expression data were obtained from The Cancer Genome Atlas 
(https://cancergenome.nih.gov) via the Genomic Data Commons (https://gdc.cancer.gov), 
using the TCGAbiolinks R package (v.2.2.6) (Colaprico et al., 2016). The dataset 
comprised 364 primary solid tumor as well as 49 matched healthy liver tissue samples. 
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For gene expression analysis, RSEM (Li & Dewey, 2011) normalized read counts were 
downloaded and log2-transformed. 
 
9.2 GEO datasets 
 
For differential gene expression analyses, 39 tumor and 39 adjacent non-tumor samples 
from the Total RNA Illumina HumanHT-12 V4.0 dataset GSE57957 were included. 
Similarly, differential gene expression was analyzed in dataset GSE54236 between tumor 
(n=74) and non-tumor (n=74) samples of an Agilent-014850 Whole Human Genome 
Microarray 4x44K G4112F (three samples without sufficient information per group were 
excluded). Additionally, the methylation of the H19 promoter region 2 kb around the 
transcription start site was analyzed using the GSE57956 dataset of bisulfite converted 
DNA from 58 tumors and 58 adjacent non-tumor samples hybridized to an Illumina 
Infinium 27k Human Methylation Beadchip (two samples without sufficient information per 
group were excluded). A subset of samples from GSE57956 was equal to the expression 
dataset GSE57957. 
 
Bioinformatic analysis was performed by Dr. Marcel Schulz and Dr. Markus List from the 
Department for Computational Biology and Applied Algorithmics (Max Planck Institut for 
Informatics, Saarland University). 
 
 
10. Clinical samples 
 
32 human paraffin-embedded liver samples of tumor and matched non-tumorous adjacent 
tissue from randomly selected pseudonymized HCC patients who underwent liver 
resection at the Saarland University Medical Center between 2005 and 2010 were 
obtained (Kessler et al., 2013). The study protocol was approved by the local Ethics 
Committee (Kenn-Nr. 47/07). Clinical data were described previously (Kessler et al., 2013, 
Kessler et al., 2014). 
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Clinical samples were prepared and collected by Dr. Juliane Pokorny and Prof. Dr. Rainer 
M. Bohle from the Institute of Pathology (Saarland University, Campus Homburg), and Dr. 
Vincent Zimmer and Prof. Dr. Frank Lammert from the Department of Medicine II 
(Saarland University Medical Center, Saarland University, Campus Homburg ). 
 
 
11. Microdissection and RT-PCR 
 
Tissue sections of paraffin-embedded (FFPE) tissues were mounted on nuclease and 
human nucleic acid free glass membrane slides, deparaffinized and stained with 
haemalaun. Laser microdissection was performed as described previously (Fink et al., 
2000, Fink et al., 1999) using a Leica LMD6000 microscope (Leica Microsystems CMS). 
Laser-microdissected cells were transferred into a reaction tube containing PKD buffer. 
RNA was isolated according to the manufacturer’s protocol “Purification of total RNA from 
microdissected FFPE tissue sections” using the RNeasy FFPE Kit. 28 ng RNA were 
reverse transcribed using random primers as described (Kessler et al., 2013). 
 
Microdissection and RT-PCR were performed by Dr. Sonja M. Kessler from the 
Department of Pharmacy (Pharmaceutical Biology, Saarland University) and Prof. Dr. 
Rainer M. Bohle from the Institute of Pathology (Saarland University, Campus Homburg). 
 
 
12. H19 RNA immunoprecipitation 
 
Immunoprecipitation (IP) of HuR-associated RNAs from Huh7 cells, validation of IP by 
western blot, and qPCR for the negative control GAPDH and the positive control Cyclin 
B1 (CCNB1) were performed as described previously (Hachenthal, 2017, Hoppstädter et 
al., 2016). The magnetic SureBeads system (Bio-Rad, Munich, Germany) was used 
according to the manufacturer`s protocol. All buffers were supplemented with RNaseOUT 
and 7x Complete protease inhibitor. Primer sequences (hu GAPDH IP, hu CCNB1 and hu 
H19 IP) and conditions for qPCR can be found in Table 4. 
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For the generation of four samples, 4.5 x 107 Huh7 cells in medium were centrifuged for 
5 min at 500 x g and 4°C. The cell pellet was washed with 1 ml ice cold PBS and lysed in 
2 ml of radioimmune precipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 1% 
Nonidet P-40, 0.5% sodium deoxycholate, 0.05% sodium dodecyl sulfate, 1 mM EDTA, 
150 mM NaCl). After centrifugation for 10 min at 16,000 x g and 4°C, the pellet was 
discarded and 500 µl of the supernatant were added to the prepared beads. After 
incubation under slight rotation for 1 h at room temperature, the samples were washed as 
described by the manufacturer, resuspended in 0.5 ml QIAzol and frozen at -80°C for at 
least 1 h. RNA isolation and qPCR were performed as described in chapter 4 with one 
modification: 6 µl of Ambion linear acrylamide (5 mg/ml), 60 µl of 5 M ammonium acetate, 
and 600 µl of isopropyl alcohol per sample were used for the mRNA precipitation at -80°C 
overnight. 
 
H19 RNA immunoprecipitation was carried out by Dr. Nina Hachenthal from the 
Department of Pharmacy (Pharmaceutical Biology, Saarland University). 
 
 
13. RFLP (restriction fragment length polymorphism) analysis 
 
Genomic DNA (gDNA) was isolated from paraffin-embedded tissues using the QIAamp 
DNA FFPE Tissue Kit according to the manufacturer’s instructions. Genomic DNA was 
amplified to screen liver tissue samples for heterozygosity at a known AluI polymorphism 
at the H19 gene (Zhang & Tycko, 1992). 9 of the 32 samples (Kessler et al., 2013) were 
heterozygous and therefore corresponding cDNA was tested for biallelic expression. 
Primer sequences used were the following: 5’-TACAACCACTGCACTACCTG-3’ (sense), 
5’-TGGCCATGAAGATGGAGTCG-3’ (antisense). The PCR reaction was performed 
using the DyNAmo Flash SYBR Green Master mix containing 400 nM primer, each. 
Amplification was performed in a Thermal Cycler (Px2 Thermal Cycler, Thermo Electron 
Corporation, Schwerte, Germany). PCR products were digested for 2 h at 37°C with AluI. 
Detection of existence of polymorphisms and expression status were done by agarose gel 
electrophoresis showing three bands (228 bp, 128 bp, and 100 bp) in gDNA after 
digestion. In case of monoallelic expression, cDNA was expected to show one 148 bp 
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band and three bands (48 bp, 100 bp, and 148 bp) in case of biallelic expression. Due to 
the high agarose concentration (3%), the 48 bp band was not detectable. 
 
RFLP analysis was performed by Dr. Sonja M. Kessler from the Department of Pharmacy 
(Pharmaceutical Biology, Saarland University). 
 
 
14. Ki67 staining 
 
Cells were detached from the plates using trypsin (Sigma-Aldrich, Taufkirchen, Germany) 
and cell staining was performed as described previously (Hoppstädter et al., 2016). For 
intracellular staining of Ki67, cells were washed with flow cytometry buffer (FCB; PBS 
containing 2.5% (v/v) bovine calf serum and 0.05% (w/v) NaN3) and fixed for 10 min in 1% 
(w/v) paraformaldehyde in PBS, pH 7.6, followed by permeabilization in SAP (FCB with 
0.2% (w/v) saponin), and blocking for 30 min in 20% FCS (v/v, diluted in SAP). Cells were 
incubated with Ki67 or isotype control antibody (10 µl in 50 μl of FCB) for 15 min on ice. 
The cells were washed in FCB and resuspended in 1% (w/v) cold paraformaldehyde in 
PBS, pH 7.6. The stained cells were examined on a BD LSRFortess cell analyzer and 
results were analyzed using the FACS Diva software (BD Biosciences, Heidelberg, 
Germany). 
 
Ki67 staining was realized by Dr. Kevan Hosseini from the Department of Pharmacy 
(Pharmaceutical Biology, Saarland University). 
 
 
15. Chromogenic in situ hybridization (CISH) 
 
Eight paraffin-embedded samples from HCC patients were investigated. The reseach 
project was authorized by the ethical committee of the Medical University of Graz (Ref. 
Nr. 20-119 ex 08/09). CISH was performed using the miCURY LNA microRNA ISH 
Optimization Kit (FFPE) according to manufacturer’s instruction. A biotin-labeled probe 
was used for the detection of H19 RNA (/5BioTEG/GTCCTGTAACCAAAAGTG ACCG). 
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A digoxin-labeled probe of scrambled RNA served as negative control 
(/5DigN/GTGTAACACGTCTATACGCCCA) and a digoxin-labeled actin beta probe was 
used as positive control (/5DigN/CTCATTGTAGAAGGTGTGGTGCCA). All probes were 
used in a concentration of 40 nM. Proteinase K digestion was done for 10 min at 37°C 
with 15 µg/ml Proteinase K. The hybridization step was performed at 56°C for 1 h in a 
slide hybridizer DakoCytomation (Dako, Hamburg, Germany). Nuclei were counterstained 
with Nuclear Fast Red Counterstain. 
 
CISH was performed by Dr. Sonja M. Kessler from the Department of Pharmacy 
(Pharmaceutical Biology, Saarland University) and samples were examined together with 
Prof. Dr. Dr. Johannes Haybaeck from the Institute of Pathology (Medical University of 
Graz) and the Department of Pathology (Medical Faculty, Otto-von-Guericke University 
Magdeburg). 
 
 
16. Statistics 
 
Data analysis and statistics were performed with Microsoft Office Excel 2013 and 
OriginPro 8.6G (OriginLab Corporation, Northampton, USA). Values were expressed as 
mean ± SEM or as box plots with 25th/75th percentile boxes, geometric medians (EASL-
Clinical-Practice-Guidelines), means (square), and 10th/90th percentile as whiskers. 
Statistical differences were calculated using an independent two-sample t-test, ANOVA 
combined with Bonferroni post hoc test, Mann-Whitney U test, or Kolmogorov-Smirnov 
test as indicated depending on whether the data were normally distributed. A Chi-square 
test was used for the statistical analysis of tumor development and characterization, 
apoptosis, and inflammation in mouse livers. 
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Part of the methods were published in: Schultheiss C.S., Laggai S., Czepukojc B., 
Hussein U.K., List M., Barghash A., Tierling S., Hosseini K., Golob-Schwarzl N., Pokorny 
J., Hachenthal N., Schulz M., Helms V., Walter J., Zimmer V., Lammert F., Bohle R.M., 
Dandolo L., Haybaeck J., Kiemer A.K., and Kessler S.M. (2017) The long non-coding RNA 
H19 suppresses carcinogenesis and chemoresistance in hepatocellular carcinoma. Cell 
Stress. 1(1), 37-54.  
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AAGCTTGGGAGGGGGTGGGATGGGTGGGGGGTAACGGGGGAAACTGGGGAAGTGGGGAACCGAGGGGCAACCAGGGGA
AGATGGGGTGCTGGAGGAGAGCTTGTGGGAGCCAAGGAGCACCTTGGACATCTGGAGTCTGGCAGGAGTGATGACGGG
TGGAGGGGCTAGCTCGAGGCAGGGCTGGTGGGGCCTGAGGCCAGTGAGGAGTGTGGAGTAGGCGCCCAGGCATCGTGC
AGACAGGGCGACATCAGCTGGGGACGATGGGCCTGAGCTAGGGCTGGAAAGAAGGGGGAGCCAGGCATTCATCCCGGT
CACTTTTGGTTACAGGACGTGGCAGCTGGTTGGACGAGGGGAGCTGGTGGGCAGGGTTTGATCCCAGGGCCTGGGCAA
CGGAGGTGTAGCTGGCAGCAGCGGGCAGGTGAGGACCCCATCTGCCGGGCAGGTGAGTCCCTTCCCTCCCCAGGCCTC
GCTTCCCCAGCCTTCTGAAAGAAGGAGGTTTAGGGGATCGAGGGCTGGCGGGGAGAAGCAGACACCCTCCCAGCAGAG
GGGCAGGATGGGGGCAGGAGAGTTAGCAAAGGTGACATCTTCTCGGGGGGAGCCGAGACTGCGCAAGGCTGGGGGGTT
ATGGGCCCGTTCCAGGCAGAAAGAGCAAGAGGGCAGGGAGGGAGCACAGGGGTGGCCAGCGTAGGGTCCAGCACGTGG
GGTGGTACCCCAGGCCTGGGTCAGACAGGGACATGGCAGGGGACACAGGACAGAGGGGTCCCCAGCTGCCACCTCACC
CACCGCAATTCATTTAGTAGCAGGCACAGGGGCAGCTCCGGCACGGCTTTCTCAGGCCTATGCCGGAGCCTCGAGGGC
TGGAGAGCGGGAAGACAGGCAGTGCTCGGGGAGTTGCAGCAGGACGTCACCAGGAGGGCGAAGCGGCCACGGGAGGGG
GGCCCCGGGACATTGCGCAGCAAGGAGGCTGCAGGGGCTCGGCCTGCGGGCGCCGGTCCCACGAGGCACTGCGGCCCA
GGGTCTGGTGCGGAGAGGGCCCACAGTGGACTTGGTGACGCTGTATGCCCTCACCGCTCAGCCCCTGGGGCTGGCTTG
GCAGACAGTACAGCATCCAGGGGAGTCAAGGGCATGGGGCGAGACCAGACTAGGCGAGGCGGGCGGGGCGGAGTGAAT
GAGCTCTCAGGAGGGAGGATGGTGCAGGCAGGGGTGAGGAGCGCAGCGGGCGGCGAGCGGGAGGCACTGGCCTCCAGA
GCCCGTGGCCAAGGCGGGCCTCGCGGGCGGCGACGGAGCCGGGATCGGTGCCTCAGCGTTCGGGCTGGAGACGAGGCC
AGGTCTCCAGCTGGGGTGGACGTGCCCACCAGCTGCCGAAGGCCAAGACGCCAGGTCCGGTGGACGTGACAAGCAGGA
CATGACATGGTCCGGTGTGACGGCGAGGACAGAGGAGGCGCGTCCGGCCTTCCTGAACACCTTAGGCTGGTGGGGCTG
CGGCAAGAAGCGGGTCTGTTTCTTTACTTCCTCCACGGAGTCGGCACACTATGGCTGCCCTCTGGGCTCCCAGAACCC
ACAACATGAAAGAAATGGTGCTACCCAGCTCAAGCCTGGGCCTTTGAATCCGGACACAAAACCCTCTAGCTTGGAAAT
GAATATGCTGCACTTTACAACCACTGCACTACCTGACTCAGGAATCGGCTCTGGAAGGTGAAGCTAGAGGAACCAGAC
CTCATCAGCCCAACATCAAAGACACCATCGGAACAGCAGCGCCCGCAGCACCCACCCCGCACCGGCGACTCCATCTTC
ATGGCCACCCCCTGCGGCGGACGGTTGACCACCAGCCACCACATCATCCCAGAGCTGAGCTCCTCCAGCGGGATGACG
CCGTCCCCACCACCTCCCTCTTCTTCTTTTTCATCCTTCTGTCTCTTTGTTTCTGAGCTTTCCTGTCTTTCCTTTTTT
CTGAGAGATTCAAAGCCTCCACGACTCTGTTTCCCCCGTCCCTTCTGAATTTAATTTGCACTAAGTCATTTGCACTGG
TTGGAGTTGTGGAGACGGCCTTGAGTCTCAGTACGAGTGTGCGTGAGTGTGAGCCACCTTGGCAAGTGCCTGTGCAGG
GCCCGGCCGCCCTCCATCTGGGCCGGGTGACTGGGCGCCGGCTGTGTGCCCGAGGCCTCACCCTGCCCTCGCCTAGTC
TGGAAGCTCCGACCGACATCACGGAGCAGCCTTCAAGCATTCCATTACGCCCCATCTCGCTCTGTGCCCCTCCCCACC
AGGGCTTCAGCAGGAGCCCTGGACTCATCATCAATAAACACTGTTACAGCAAAAAAAAAAAAAAAATCTAGA 
 
 
Supplemental Figure S1: (A) Plasmid map (pcDNA3.1(+)_A009) and (B) H19-sequence (2,334 bp) (Ref. 
No.: 1381790).  
Supplemental information 
100 
 
 
Supplemental Figure S2: H19 expression in HCC tissues from Saarland University Medical Center 
determined by qPCR (each, n=32, Mann-Whitney U test; see Figure 1D). Highlighted are the two highest 
expressing HCC tissues and corresponding normal tissues, from which hepatocytes were microdissected 
and compared with hepatocytes from three low expressing HCC tissues.  
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Supplemental Figure S3: Effect of H19 overexpression on colony formation ability in stably H19 
overexpressing (H19) and vector control (control, co) HepG2 (left panels), Plc/Prf/5 (middle panels), and 
Huh7 (right panels) cells. (A, B) Colony formation ability of control or H19 cells normalized to their respective 
untreated controls after (A) doxorubicin (n≥3, duplicates) or (B) sorafenib (n=3, triplicates) treatment. The p 
values were calculated by two-sample t-test or Mann-Whitney U test depending on the data distribution. * p 
< 0.05, ** p < 0.01, *** p < 0.001.  
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Supplemental Figure S4: Cytotoxicity estimated by MTT assay after treatment with DMSO in (A) 
HepG2, (B) vector control transfected HepG2, or (C) stably H19 overexpressing HepG2 cells normalized to 
the respective untreated control (n=1, octuplicates). 
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Supplemental Figure S5: Cytotoxicity estimated by MTT assay after treatment with DMSO in (A) 
Plc/Prf/5, (B) vector control transfected Plc/Prf/5, or (C) stably H19 overexpressing Plc/Prf/5 cells 
normalized to the respective untreated control (n=1, octuplicates). 
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Supplemental Figure S6: Cytotoxicity estimated by MTT assay after treatment with DMSO in (A) Huh7, 
(B) vector control transfected Huh7, or (C) stably H19 overexpressing Huh7 cells normalized to the 
respective untreated control (n=1, octuplicates).  
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Abbreviations 
 
°C   degree Celsius 
3‘-UTR  3‘-untranslated region 
ABCB1  ATP binding cassette subfamily B member 1 
ACTB   actin beta 
AFLD   alcoholic fatty liver disease  
AFP   alpha-fetoprotein 
ANOVA  analysis of variance 
ARE    AU-rich elements 
AT   annealing temperature 
atto    10−18 
b    bases 
BCL2   B-cell CLL/lymphoma 2 
BCLC   Barcelona Clinic Liver Cancer 
bp    base pair 
BRCA1  breast cancer 1 
C57BL/6J  C57 black 6 J 
CALN1  calneuron 1 
CCNB1  cyclin B1 
CDC6   cell division cycle 6 
CDH-11  cadherin 11 
CDH-13  cadherin 13 
cDNA   complementary DNA 
ceRNA  competing endogenous RNAs  
CISH   chromogenic in situ hybridization 
cm2   square centimetre 
CSNK2A2  casein kinase 2 alpha 2 
CTSV   cathepsin V 
Da    Dalton 
DCDHF  dichlorodihydrofluorescein diacetate 
Abbreviations 
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ddCTP  dideoxycytidine triphosphate 
ddTTP  dideoxythymidine triphosphate 
DEN    diethylnitrosamine 
DLK1   delta-like 1 homolog 
DMSO  dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
DNase   deoxyribonuclease 
DNMT3B  DNA methyltransferase 3 beta 
dNTP   deoxyribonucleoside triphosphate 
DSMZ   Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH  Gesellschaft mit beschränkter Haftung 
DTT   dithiothreitol 
E2F8   E2F transcription factor 8 
EDTA   ethylenediaminetetraacetic acid 
ELAVL1  ELAV-like RNA-binding protein 1 
EMT    epithelial to mesenchymal transition  
ExoSAP  exonuclease shrimp alkaline phosphatase 
FACS   fluorescence-activated cell sorting 
FADD   anti-apoptotic Fas-associated via death domain 
FCB   flow cytometry buffer 
FCS   fetal calf serum 
g    gram 
g    gravitational force 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
gDNA   genomic DNA 
GDP   guanosine diphosphate 
GEO   gene expression omnibus 
Gp73    Golgi membrane protein 73 
GS   glutamine synthetase 
GST   glutathione S-tranferase 
GTP   guanosine triphosphate 
h    hour 
Abbreviations 
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H&E    haematoxylin-eosin 
H2AFY2  H2A histone family member Y2 
HBV    hepatitis B virus 
HCC    hepatocellular carcinoma 
HCV    hepatitis C virus 
HOTS   H19 opposite tumor suppressor 
HPLC   high performance liquid chromatography 
hu   human 
IGF    insulin-like growth factor 
IGF1R  IGF1 receptor 
IGF2BP1  IGF2 mRNA-binding protein 1 
IGF2R  IGF2 receptor 
IKBKAP  inhibitor of kappa light polypeptide gene 
IMP   IGF2 mRNA-binding proteins 
IP   immunoprecipitation 
IP/RP-HPLC  ion pair reversed phase HPLC 
k   kilo 
KDELC1  KDEL motif containing 1 
ko   knockout  
KSRP   K homology-type splicing regulatory protein 
l    litre 
LAP   liver-enriched activator protein 
LCC   large cell changes 
LNA   locked nucleic acid 
lncRNA  long non-coding RNA 
LOI    loss of imprinting 
m    metre or milli (10-3) 
M    molar 
MBD1   methyl-CpG-binding protein domain 1 
MDR1   multi-drug resistance protein 1 
MgCl2   magnesium chloride 
min   minute 
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miRNA  microRNA 
MITF   melanogenesis-associated transcription factor 
MPI-I   Max Planck Institut for Informatics 
mRNA   messenger ribonucleic acid 
MTT   thiazolyl blue tetrazolium bromide 
mu   murine 
MYBL2  MYB proto-oncogene like 2 
n    nano (10-9) or size of a statistical sample or number of experiments 
NaCl    sodium chloride 
NAFLD   non-alcoholic fatty liver disease 
NaN3   sodium azide 
NASH   non-alcoholic steatohepatitis 
ncRNA  non-coding RNA 
Neo (R)  neomycin resistance gene 
NINL   ninein like 
NOMO 1  nodal modulator 1 
ORF   open reading frame 
p    probability (value) 
PAGE   polyacrylamide gel electrophoresis 
PBD   p21 binding domain 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
piRNA  Piwi-associated RNA 
PKD   digestion buffer 
PMSF   phenylmethylsulfonyl fluoride 
qPCR   real-time quantitative polymerase chain reaction 
RAC1   ras-related C3 botulinum toxin substrate 1 
RB    retinoblastoma 
RBB   Rockland Blocking Buffer 
RBP    mRNA-binding protein 
Ref. No.  reference number 
RFLP   restriction fragment length polymorphism 
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RIPA   radioimmune precipitation assay 
RNA    ribonucleic acid 
RNA18S5  18S ribosomal 5 
RNAse  ribonuclease 
RNU6B  RNA U6 small nuclear 6 pseudogene 
ROS   reactive oxygen species 
RPMI    Roswell Park Memorial Institute 
rRNA   ribosomal RNA 
RSEM  RNA-Seq by Expectation Maximization 
RUNX1  runt related transcription factor 1 
SCC   small cell changes 
SDS   sodium dodecyl sulfate 
sec   second 
SEM    standard error of mean 
seq    sequencing 
siRNA   small interfering RNA 
SLC15A1  solute carrier family 15 member 1 
SMAD1  SMAD family member 1 
SMAD5  SMAD family member 5 
SMYD3  SET and MYND domain containing 3 
snoRNA   small nucleolar RNA 
snRNA   small nuclear RNA 
SNuPE  single nucleotide primer extension 
SOAT2  sterol O-acyltransferase 2 
SPONGE  sparse partial correlation on gene expression 
SV40   simian virus 40 
TA   transactivator 
TBARS   thiobarbituric acid reactive substances  
TCGA   The Cancer Genome Atlas 
tg   transgene 
TGFBI   transforming growth factor beta induced protein 
TRE-CMV  transrepressive responsive element cytomegaly virus 
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tRNA   transfer RNA 
tTA   tetracycline transactivator 
v/v    volume per volume 
VDR   vitamin D receptor 
w/v    weight per volume 
WASF1  WAS protein family member 1 
wt   wild-type 
µ   micro (10-6) 
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